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ABSTRACT 
 
CHRISTOPHER SCHMITT: Identification of Novel Transcription Factors Regulating 
Recovery of the Endothelial Lineage in Avascular Mutants                                      
(Under the direction of Dr. Suk-Won Jin) 
 
Multiple mesodermal tissues are known to give rise to endothelial cells during development.  
Furthermore, markers for functionally distinct endothelium are well established. Therefore, it is likely that 
multiple distinct populations of endothelial cells exist during development and into adulthood.  Two 
zebrafish mutants, cloche and groom of cloche provide a unique opportunity to interrogate the 
heterogeneous origin of the endothelial lineage.  Homozygous mutant embryos lack the majority of the 
endothelial lineage at early developmental stages, however, generate rudimentary vessels at later stages, 
indicating that they retain the ability to generate endothelial cells despite this initial lack of early 
endothelial progenitors.  To delineate the developmental source of the endothelial cells in these avascular 
mutant embryos, we first performed lineage tracing from early gastrula to determine the fate of mesoderm. 
Consistent with their phenotype, we found an increase of kdrl- unspecified mesoderm, indicating that 
much of the mesoderm apportioned to become angioblasts fails to become specified.  Conversely, 
endothelial differentiation from the tailbud, a proposed secondary source of endothelial cells during 
development, was largely unperturbed. Consistent with this finding, the majority of the early kdrl+ cells 
found in avascular mutant embryos are specified from tailbud.  To better elucidate the molecular basis of 
endothelial recovery in avascular mutant embryos, we analyzed the gene expression profile using 
microarray analysis on isolated mutant endothelial cells.  We find that the expression of the genes 
characteristic of other mesodermal lineages are substantially elevated in kdrl+ cells isolated from 
avascular mutant embryos.  Subsequent validation identified two transcription factors, sox11b and pax9, 
both of which have not previously implicated in vascular development.  Yet, we confirmed that both genes 
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are expressed in the vasculature and knockdown of either gene results in a vascular phenotype.  
Additionally, we found that the function of Pax9 appears to be evolutionarily conserved.  Taken together, 
our analyses illustrate a complex regulation of endothelial specification and differentiation during 
vertebrate development. Furthermore, we have identified two new key transcription factors involved in 
vascular development. 
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Chapter 1 
Introduction 
Emergence of the vascular system. 
The vascular system is comprised of multiple cell types that allow for 
circulation of blood, nutrients, water and waste.  Vascular smooth muscle cells, 
mural cells, and endothelial cells make up this complex system that is essential 
for the development, growth, and survival of a vertebrate organism.  Endothelial 
cells line the vessels and mediate the exchange of oxygen between blood and 
surrounding tissues.  In addition to diseases directly involving the vasculature 
such as thrombosis, numerous pathologies are exacerbated by aberrant vascular 
patterning or regulation [1].  During development, endothelial cells undergo 
morphogenetic events, which can be separated into two different processes: 
vasculogenesis and angiogenesis.  Vasculogenesis is characterized by the 
formation of new blood vessels de novo, during mid-stages of somitogenesis, 
while subsequent formation of blood vessels from pre-existing vessels is 
collectively referred to as angiogenesis.   
During development, endothelial cells are specified from the mesoderm 
during early stages of gastrulation in close proximity to hematopoietic cells [2].  In 
mouse, er71/etv2 is shown to be necessary for the proper specification 
endothelial cells [3], as is T-cell acute lymphocytic leukemia protein 1 (TAL1) [4].  
Similarly, in zebrafish, it has been shown that prior to kdrl expression, 
angioblasts express the ets-domain transcription factor, etv2 within the lateral 
plate mesoderm [5].  Subsequently, angioblasts express kdrl and migrate into the 
midline.  These angioblasts coalesce and form a primitive vascular cord in the 
midline of the embryo [6, 7].  During development, the vertebrate endothelial 
lineage arises from mesodermal tissues.  It has been reported that diverse 
mesodermal tissues including lateral plate mesoderm[8], blood islands within the 
yolk sac[9, 10], allantois[11], somitic mesoderm[12], as well as placenta[13, 14], 
can produce endothelial cells during development.  Moreover, the entire 
mesoderm excluding notochord and prechordal mesoderm can serve as sources 
for endothelial cells[15], suggesting that angiogenic potential might be one of the 
intrinsic properties of the developing mesoderm.  In addition, almost every cell in 
a 16 or 32-cell stage Xenopus embryos was fate-mapped and shown to give rise 
to endothelial cells, indicating the diverse origin of endothelial cells [16].  In 
addition, lineage tracing studies have indicated that a small portion of the 
endothelial lineage comes from hemangioblast, a common progenitor of both 
hematopoietic and vascular lineages [17].  Subsequently, endothelial cells further 
differentiate as arterial, venous or lymphatic endothelial cells, each of which 
possesses unique molecular and cellular characteristics. 
Not only do endothelial cells originate from spatially distinct populations, 
they emerge during separate waves of differentiation during development.  For 
instance, previous works in zebrafish have shown that endothelial progenitors 
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migrate from the lateral plate mesoderm at multiple time points during 
development [6], suggesting that the differentiation of endothelial progenitors is 
also regulated in a temporal manner.  During development, lateral plate 
mesoderm-derived angioblasts have been shown to give rise to the majority of 
trunk vasculature [6].  In zebrafish, it has been shown that the tailbud also 
contributes to the endothelial lineage in a WNT-dependant manner [18].  That is, 
Wnt signaling regulates the formation of the endothelial lineage within the tailbud 
mesoderm, without obvious effects on the lateral plate mesoderm [18].  In fact 
the majority of caudal vasculature is derived from tailbud (Schmitt et al, 
submitted).   
Subsequent processes, termed angiogenesis include arterio-venous 
specification and formation of secondary vessels.  Conventional wisdom is that 
the majority of new vessels form by angiogenesis after early development.  After 
early developmental stages, there is evidence for continued vasculogenesis 
mediated by circulating endothelial progenitor cells, which are thought to repair 
vascular damage and contribute to angiogenesis [19, 20].  Nonetheless, 
pathological models have indicated that de novo angioblast specification may 
occur in adult tissues.  For instance, neuroblastoma stem cells have been shown 
to have the capacity to give rise to endothelial and these cultured cells are wholly 
derived from ectoderm [21].  Despite recent progress, the molecular and cellular 
mechanisms that regulate the specification and differentiation of endothelial 
lineage remain elusive.  Given their diverse function and morphology, it is 
plausible that the endothelial lineage emerges from heterogeneous populations 
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of progenitors during development [22].  And by delineating novel transcriptional 
programs directing vasculogenesis and angiogenesis, therapeutics for a wide 
variety of diseases can be created. 
Genetic and Molecular Mechanisms of Vascular Development 
As previously mentioned specification and differentiation of the endothelial 
lineage is regulated by multiple arrays of signaling pathways and transcription 
factors.  Many of these pathways play key roles during angiogenesis.  Previous 
research has identified key signaling pathways that modulate the patterning and 
proliferation of endothelial cells, including Vascular Endothelial Growth Factor 
(VEGF)[23, 24], Fibroblast Growth Factor (FGF)[25, 26], Wnt[27], and Bone 
Morphogenetic Protein (BMP)[28], as well as essential transcription factors such 
as ETS transcription factor family member, Etv2/ER71 and FLI1 [29].  
Molecular and cellular analyses have led to the characterization of many 
markers of arterial, venous and lymphatic endothelium [30].  There have been 
many genes characterized which mark only subsets of endothelial cells [30].  For 
instance, it is well established that ephrinB2, notch1b, and tbx20 are 
preferentially expressed within arterial endothelial cells, while ephB4, disabled2, 
and nr2f2 (COUP-TFII in mouse) are selectively expressed within venous 
endothelial cells during development [30, 31].  Even endothelial cells residing 
within the same vessel display high level of heterogeneity.  For instance, a 
subset of endothelial cells within the dorsal aorta differentiate as a hemogenic 
endothelium and express hematopoietic stem cell markers runx1 and c-myb, 
while retaining the molecular properties of endothelial cells [32-34].  In addition, 
5 
	
certain markers such as sox17 appear to be expressed at varying levels in cells 
within the same vessel (Fig. 1.3).  Therefore, multiple lines of evidence support 
the prevalent heterogeneity within the endothelial lineage. 
Consistent with the observation that the developmental origin of the 
endothelial lineage is diverse, subtypes of endothelial cells appear to possess 
distinct molecular and cellular properties. Indeed, it has been shown that 
subtypes of endothelial cells distinctively respond to extracellular signaling.  EG-
VEGF was shown to promote proliferation of endocrine gland endothelium 
selectively over other types of endothelial cells [35].  It was further shown that 
this mitogen, EG-VEGF, elicited very little response from endothelial cells in 
other tissues, such as cornea or skeletal muscle, indicating that endothelial cells 
from different tissues may have distinct molecular identities [35].  We have 
recently reported that BMP2 signaling selectively activates venous endothelial 
cells without very little influence arterial endothelial cells [36].  This effect was 
shown to be important in multiple venous tissues such as caudal vein plexus and 
sub-intestinal vein [36].  While markers of arterial or venous identity have been 
well established, selective response to angiogenic cues is relatively new.  
Expression of genes in the Notch pathway [37] as well as a transcription factor, 
hlx-1 [38], have been shown to determine tip versus stalk cell phenotype in the 
developing vasculature.  Therefore, even transient changes in expression levels 
of genes within endothelial cells can greatly affect behavior and phenotype.  
Taken together, the vertebrate endothelial lineage is comprised of a 
multiple populations of cells with multiple origins and different molecular 
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programs.  Therefore, identification of additional factors that regulate 
specification and differentiation of the endothelial lineage will help to further study 
the genetic mechanisms of vascular development. 
cloche and groom of cloche, two avascular zebrafish mutants 
Zebrafish has been extensively used to study cardiovascular development 
and is an excellent model to delineate the cellular and molecular mechanisms 
that contribute to heterogeneity within the endothelial lineage.  Since embryos 
are transparent[39] and begin circulation by 24 hours post fertilization (hpf)[40], 
the zebrafish allows for short completion of experiments.  A high fecundity allows 
for the collection of data with a large sample size [41].  Additionally, the embryos 
are small enough that development can proceed in the absence of heartbeat, 
induced chemically or genetically [42].  Furthermore, zebrafish vascular 
development is remarkably similar to mammalian development.  The stepwise 
timing of events such as vascular cord coalescence, arterio-venous specification, 
onset of circulation, intersegmental vessel angiogenesis, and lymphangiogenesis 
recapitulate that which is observed in mammalian systems [39].  
Previous attempts have been made to harness the attributes of zebrafish 
as a model system to better understand development of higher vertebrate 
species.  For instance, several forward genetic screens have identified many 
mutations with altered development of the endothelial lineage [43].  One 
mutation, cloche (clo), is particularly interesting.  Homozygous clo mutant 
embryos lack kdrl+ endothelial cells as well as gata1+ or gata2+ hematopoietic 
progenitors, supporting the notion of a hemangioblast [44].  Named cloche, 
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because of the cardiac morphology of mutant resembles a bell (“cloche” in 
French).  Lineage tracing studies have determined that the increase in 
myocardial lineage is at the expense of most hematopoietic, endocardial and 
endothelial lineages, indicating common progenitors for these lineages in 
development [45].  Although the nature of the locus that is affected by clo 
mutation is currently unknown, it appears to be the one of the earliest genes 
involved in endothelial differentiation since over-expression of several known 
factors alleviate the phenotype of homozygous mutant embryos.   Nevertheless, 
clo homozygotes display a dramatic early absence of scl+, gata1+, pu.1+, and 
kdrl+ lineages, leading to embryonic lethality at around 7dpf [46].  
To identify additional factors involved in vascular development, a large 
scale forward genetic screen was performed using Tg(kdrl:eGFP)s843 transgenic 
zebrafish, which labels all endothelial cells with eGFP.[25]  From the screen, we 
have identified a novel mutant, groom of cloche (grc), which lacks the majority of 
the endothelial lineage at early stage[47], which is reminiscent of previously 
isolated mutant, cloche (clo) that lacks both endothelial and hematopoietic 
lineages[44].  Additionally, we found that other mesodermal lineages are not 
perturbed using in situ hybridization.  Using high-throughput genome and 
transcriptome sequencing, we determined that grc-/- embryos have a point 
mutation causing a leucine to proline amino acid change in the etv2 gene, also 
known as etsrp/er71.  Mutations in this gene with similar phenotypes have also 
been reported as it appears to function to specify the majority of endothelium 
from lateral plate mesoderm.[48]  Although much of the early kdrl+ lineage is 
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missing or delayed in these mutants, a crude vascular network does form in both 
grc and clo homozygotes.  Despite the lack of endothelial cells at early stages, 
these avascular mutant embryos can generate endothelial cells at later 
stages[47], suggesting that distinct molecular mechanisms may be used to 
modulate the emergence of the endothelial lineage in these embryos. 
Nevertheless, both mutants retain a small population of kdrl+ progenitors 
which subsequently undergo vasculogenesis and angiogenesis, such as 
formation of intersegmental vessels.  Additionally, grc are distinct from clo in that 
homozygotes have been raised to adulthood and are viable. I have hypothesized 
that the majority of kdrl+ cells in both mutants are derived from tailbud and that 
grc is able to specify some angioblasts from the lateral plate mesoderm (Figure 
1.1 Panel A).  Using the Tg(kdrl:EGFP) transgenic line, we found that kdrl+ cells 
appear in homozygous grc and clo embryos as early as 18.5 hpf (shown in 
Figure 1.1 panel C).  While kdrl+ cells found in homozygous clo embryos are 
clustered within the intermediate cell mass (ICM), which is located in the 
posterior region of the embryos, those found in homozygous grc embryos are 
also clustered in this region with sparse kdrl+ cells along the entire body axis, 
indicating that some lateral plate-derived angioblasts are specified in grc.  
Interestingly, kdrl+ cells in grc or clo homozygous embryos fail to express cdh5 
(VE-Cadherin), suggesting that these cells are not fully differentiated endothelial 
cells.  Therefore, the kdrl+ cells found in these embryos appear to be a unique 
population, and might be distinct in their molecular and cellular characteristics.  
Due to this apparent lack of majority of endothelial lineage in both mutants, we 
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hypothesized that the existing kdrl+ cells are able to be specified despite their clo 
or grc genetic backgrounds.  Furthermore, this apparent resiliency may indicate a 
unique transcriptional program or developmental origin.  
As seen in Figure 1.1 Panel B (white arrows), GFP+ cells arise in the 
caudal region of the embryo, posterior to the yolk-extension.  Vasculature in 
these mutants is aberrant.  This may be due to a developmental delay where 
kdrl+ cells are specified at a later time and therefore miss their proper migratory 
cues or are intrinsically unable to pattern properly.  
Research presented in this dissertation 
The majority of this thesis is based upon a pilot experiment that involved 
the transcriptional profiling of kdrl+ cells in the early mutant embryos to elucidate 
alternative mechanisms of vasculogenesis and/or angiogenesis.  In Chapter 2, 
we performed Significance analysis of microarrays (SAM) [49] to reveal the 
molecular profile of avascular mutant kdrl+ cells. We isolated kdrl+ cells using 
FACS sorting and profiled their transcriptome using microarray analyses and 
found that the relative levels of thousands of mRNAs in both mutants compared 
to wild-type was significantly different. Screening these lists for transcription 
factors, we identified 43 transcription factors that were greater than two-fold 
upregulated in avascular mutant kdrl+ cells. Using morpholino-mediated 
knockdown, the function of one transcription factor, SRY-related HMG Box 11b 
(sox11b), was interrogated and found to be necessary for proper vascular 
patterning, particularly sprouting angiogenesis.  
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In Chapter 3, I focused on another validated transcription factor, pax9, 
which was found to preferentially affect avascular mutant secondary vessel 
morphogenesis.  I characterized the novel mutation, grc, which lacks a majority 
of endothelial cells by evaluating the phenotype, the mode of action of grc and 
cloning of the genetic lesion.  Using lineage tracing in early gastrula, I determined 
that much of the mesodermal lineage defaults to an unspecified mesodermal-
subtype in the absence of clo or etv2 function.  Additionally, using tailbud lineage 
tracing found that the majority of kdrl+ cells in these mutants are derived from the 
tailbud as opposed to lateral plate mesoderm.   
Using multifaceted approaches, we validated a subset of transcription 
factors indicated to be upregulated by the array and found that two, pax9 and 
sox11b, were involved in vascular morphogenesis.  Taken together, the research 
presented in this dissertation includes multiple novel findings.  Foremost, kdrl+ 
cells in clo or grc have a unique transcriptional profile.  These endothelial cells 
are dependent on pax9 for proper morphogenesis (summarized in Figure1.3).  
Much of the avascular mutant endothelial cells come from tailbud mesoderm as 
opposed to lateral plate mesoderm.  Our model has allowed for the discovery of 
new genes involved in vascular development.  Our results demonstrate that 
developmental ontogeny of the endothelial lineage is far more complex than 
previously thought.  The research in this thesis expands our current 
understanding on how spatial, developmental and molecular heterogeneity within 
the endothelial lineage is a real phenomenon and is regulated during 
development.  Considering that dysregulation of angiogenesis is frequently 
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associated with the onset and subsequent progression of various pathological 
conditions, including cancer, retinopathy, and diabetes, knowledge obtained from 
the thesis research present here may help us to develop anti- or pro-angiogenic 
therapies selectively targeting sub-populations of endothelial cells. 
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Fig. 1.1. Emergence of the endothelial lineage in zebrafish embryos.  
 
(A) Schematic diagram illustrating the location of emerging endothelial 
cells in wild-type (left), grc/etv2 (middle), and clo (right) embryos.  The top row is 
a depiction of a dorsal view of 12-15 somite embryos. Lateral plate mesoderm 
(lpm), Somite (s), Pre-somitic mesoderm (psm) and tailbud (tb) are all depicted in 
the wild-type embryo.  Green arrows indicate angioblast migration into the 
midline.  (B) Brightfield micrographs of 18.5 hpf wild-type (left), grc/etv2 (middle), 
and clo (right) embryos.  (C) epifluorescent micrographs of 18.5 hpf wild-type 
A 
B 
C 
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(left), grc/etv2 (middle), and clo (right) embryos in Tg(kdrl:eGFP) transgenic 
background.  The only apparent kdrl+ lineage in the avascular mutants is the 
pharyngeal endoderm at 18.5 hpf, though kdrl+ cells are present in the midline 
(Data not shown). 
 
 
 
 
 
 
 
 
 
Fig. 1.2. An example of endothelial heterogeneity.  
Flattened confocal z-stacks image series taken from the caudal vein 
plexus of a 72 hpf Tg(sox17:eGFP;kdrl:mCherry) embryo.  Lateral view; anterior 
left and posterior right. Intersegmental vessels (ISV), dorsal aorta (DA), dorsal 
vein (DV), and ventral vein (VV) are labeled.  White arrows indicate double 
positive cells. Scale bar= 30μM.    
 
ISV 
VV 
DA 
DV 
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Fig. 1.3. Model incorporating data from this thesis.  
Vasculogenesis and angiogenesis in wild-type (left) and avascular mutant 
(right) embryos during development.  1) In the absence of clo or etv2, alternative 
mechanism(s) may facilitate specification of angioblasts to compensate the initial 
deficit of the endothelial lineage.  2) While Notch, WNT and VEGF modulation all 
seemed to affect vascular morphogenesis in avascular mutants, BMP appears to 
be less important.  3) sox11b only affected wild-type vascular morphogenesis. 4) 
pax9 is dispensable for wild-type angiogenesis, yet essential for avascular 
mutant angiogenesis. 
#1
#2
#3 #3’
#2’
#4 
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CHAPTER 2 
Mutant-Specific Gene Expression Profiling Identifies SRY-Related HMG Box 
11b (Sox11b) as a Novel Regulator of Vascular Development in Zebrafish 
 
Summary 
Previous studies have identified two zebrafish mutants, cloche and groom of 
cloche, which lack the majority of the endothelial lineage at early developmental 
stages.  However, at later stages, these avascular mutant embryos generate 
rudimentary vessels, indicating that they retain the ability to generate endothelial 
cells despite this initial lack of endothelial progenitors.  To further investigate 
molecular mechanisms that allow the emergence of the endothelial lineage in these 
avascular mutant embryos, we analyzed the gene expression profile using 
microarray analysis on isolated endothelial cells.  We find that the expression of the 
genes characteristic of other mesodermal lineages are substantially elevated in the 
kdrl+ cells isolated from avascular mutant embryos.  Subsequent validation and 
analyses of the microarray data identifies Sox11b, a zebrafish ortholog of SRY-
related HMG box 11 (SOX11), which has not previously implicated in vascular 
development.  We further define the function of sox11b during vascular 
development, and find that Sox11b function is essential for developmental 
angiogenesis in zebrafish embryos, specifically regulating sprouting angiogenesis.  
Taken together, our analyses illustrate a complex regulation of endothelial 
specification and differentiation during vertebrate development. 
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Introduction 
Endothelial cells are a major component of the vascular system, which is 
essential for the development, growth, and survival of an individual.  Failures in 
regulating the development of endothelial lineage contribute to a wide variety of 
pathological conditions, including cancer, psoriasis, arthritis, congenital or inherited 
diseases, as well as heart and brain ischemia, neurodegeneration, and osteoporosis 
[1].  During development, the endothelial lineage arises from mesodermal tissues. It 
has been reported that diverse mesodermal tissues including lateral plate mesoderm 
[2], blood islands within the yolk sac [3,4], allantois [5], somitic mesoderm [6], as well 
as placenta [7,8], can produce endothelial cells during development.  Moreover, the 
entire mesoderm excluding notochord and prechordal mesoderm can serve as 
sources for endothelial cells [9], suggesting that angiogenic potential might be one of 
the intrinsic properties of the developing mesoderm.  Subsequently, endothelial cells 
further differentiate as arterial, venous or lymphatic endothelial cells, each of which 
possesses unique molecular and cellular characteristics. 
Specification and differentiation of the endothelial lineage are regulated by 
arrays of signaling pathways and transcription factors.  Many pathways that regulate 
the emergence and organization of the endothelium have been characterized such 
as receptor tyrosine kinases [10,-13], G-protein signaling pathways [14], serine-
threonine kinase [15], as well as transcription factors [16-17]. Overall, many of these 
pathways are preferentially required for the proper development of a subset of 
vasculature, such as cranial versus trunk or arterial versus venous endothelium.  
This is not surprising given the numerous developmental sources of endothelial 
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cells.  One of the most striking examples is that of BMP2 signaling, which is 
preferentially required for venous endothelial development in zebrafish [18].  
Similarly, Wnt signaling regulates the formation of the endothelial lineage within the 
tailbud mesoderm, without obvious effects on the lateral plate mesoderm [19].  
Therefore, identification of additional factors that regulate specification and 
differentiation of the endothelial lineage will help us to further delineate the 
heterogeneity of endothelial cells. 
From a forward genetic screen [20], we have isolated a mutant, named groom 
of cloche (grc), which lacks the majority of early Tg(kdrl:eGFP)+ cells [21], which is 
reminiscent of another mutant, cloche (clo) that lack displays a severe deficiency of 
both hematopoietic and endothelial lineages [22].  Nevertheless, both mutant 
embryos recover [21].  This indicates that alternative mechanisms for the emergence 
of the endothelial lineage.  
In this report, we performed microarray analysis using the endothelial cells 
isolated from late stage avascular mutant embryos and compared the expression 
profile of transcription factors with endothelial cells isolated from wild-type embryos.  
We find that the expression level of 43 transcription factors is significantly up-
regulated in endothelial cells isolated from avascular mutant embryos.  The majority 
of transcription factors we identified in our microarray have not been implicated in 
vascular development.  We further analyze the function of one of these transcription 
factors, SRY-related HMG Box 11b (Sox11b), in endothelial differentiation and 
subsequent vascular patterning.  We find that Sox11b is expressed in endothelial 
cells during development, and is essential for sprouting angiogenesis in zebrafish. 
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Our results demonstrate that developmental ontogeny of the endothelial lineage is 
far more complex than previously thought. 
 
Experimental Methods 
Zebrafish Husbandry 
Zebrafish (Danio Rerio) embryos were raised as previously described [23].  
The following transgenic and mutant fish lines were utilized: Tg(kdrl:eGFP)s843 [20], 
cloche (clo)s5 [22], Casanova (cas)s4 [24], groom of cloche (grc)s635 [21]. 
Florescent Activated Cell Sorting (FACS) and RNA Isolation 
18.5 hpf Tg(kdrl:eGFP)s843 embryos were dissociated in HBSS with 5% FBS 
and subsequently incubated with 100μg/ml Liberase solution (Roche) for 15 minutes 
at 37°C.  Embryos were then triturated and the resulting suspension was pushed 
through a 40μM cell culture filter (BD Biosciences) and the reaction was stopped 
using 5mM EDTA, pH 8.0 in HBSS minus Ca2+ and Mg2+.  Gates for flow cytometry 
were selected based on the Phycoerythrin versus FITC plot.  Double sorts indicated 
an enrichment to >95% GFP+ cells.  RNA was extracted from isolated cells using 
Trizol (Invitrogen) and the accompanying protocol.  Multiple rounds of flow cytometry 
were performed and RNA for each biological replicate was pooled. 
Microarray Analyses and quantitative RT-PCR 
The WT ovation Pico Kit was used to amplify the RNA samples to satisfactory 
RNA integrity score (RIN) score [25].  Otherwise, gene expression profiling was 
performed as previously described [26] using an Agilent Zebrafish array version 2. 
Using the Statistical Analysis of Microarrays (SAM), the raw data for wild-type, grc, 
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clo and cas was analyzed.  We disregarded genes whose expression was down-
regulated in cas, which would represent genes expressed in pharyngeal endoderm.  
Genes highly significantly up-regulated (q=0, fold change > 2) in both grc and clo 
mutants were further analyzed. 
For qRT-PCR, RNA was extracted using the QIagen RNeasy mini kit and 
accompanying protocol opting to add 300ng of carrier RNA to each sample. The 
iScript cDNA synthesis kit (Bio-Rad) was used to transcribe entire RNA extracts, 
immediately after RNA extraction.  cDNA samples were then diluted to a volume of 
300μl.  Using 2X Power syber mastermix, 640nM of each primer, and 8μl of cDNA in 
a 25μl reaction, amplification of transcript amplicon was monitored on a Bio-Rad 
cfx96 system.  Gene expression was normalized to either 18S rRNA or B-actin 
housekeeping genes.  Melting curve analysis was performed on all reactions. Ct 
versus cDNA concentration plots were also used to determine that there was a linear 
ratio of amplification of housekeeping genes to gene-of-interest at a particular cDNA 
concentration.  Data was analyzed using the 2-∆∆CT method [27].  At least three 
biological replicates of three technical replicates were performed for each conditon. 
Primers used were:  
18s rRNA (5'-CACTTGTCCCTCTAAGAAGTTGCA-3' and  
5'-GGTTGATTCCGATAACGAACGA-3'), sox11b  
(5'-CGAGTTCCCGGACTATTGCA-3' and 5' TCTCCCGCGATCATCTCACT-3'),  
zfhx4 (5'-CTCCTTTGTGTGGGAAGCAT-3' and  
5'-CCCTGAATGTGGAACAGCAT-3'), and klf5l  
(5'-AACCCGCAGTGAGAATCGCAAC-3' and  
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5'-ATCCATCTCCATCCGTGTCTGAGC-3'). 
in situ probe synthesis  
Probes were synthesized using the SP6/T7 DIG-UTP labeling kit (Roche) 
from linearized template.  RNA was quantified, monitored by agarose gel 
electrophoresis for a singular product, diluted in in situ hybridization solution to 
100ng/μl and stored at -20°C. 
Morpholino knockdown of sox11b 
Previously reported and validated sox11b morpholino  
(5'-CATGTTCAAACACACTTTTCCCTCT-3'), which blocks peptide synthesis, and 
control morpholino  
(5'-CCTCTTACCTCAGTTACAATTTATA-3') were used [28].  All embryos were 
injected with 4.6nL of injection mix containing 5μM HEPES, pH 7.6 and 10% Phenol 
red as a tracer. 
 
Results 
As previously reported, both clo and grc homozygous mutant embryos lack 
endothelial cells at 18 hpf [21,22] (data not shown).  However, at 72 hpf, kdrl+ cells 
were present in these avascular mutant embryos (Figure 1A-1C).  Interestingly, 
counterstaining with DAPI in this experiment also showed that the midline region 
where are exclusively populated by kdrl+ cells in wild-type embryos also contains a 
substantial number of kdrl- cells in avascular mutant embryos (Figure 1A yellow 
asterisks), alluding that vascular progenitors in these embryos may fail to undergo 
proper differentiation. 
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To better understand molecular mechanisms underlying the recovery of 
endothelial lineage, we analyzed the transcriptional profile of kdrl+ cells in wild-type 
and avascular mutant embryos by microarray analyses (Figure 2A).  Since kdrl, a 
zebrafish ortholog of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) [29], 
is also expressed in pharyngeal endoderm [20], it is possible that a significant 
portion of kdrl+ cells isolated in avascular mutant embryos may represent non-
endothelial lineage.  Therefore, we used homozygous cas embryos wherein the 
entire presumptive endoderm fails to specify with little apparent effect on the 
vasculature [20].  Genes down-regulated in kdrl+ cells isolated from homozygous cas 
mutant embryos were discarded prior to further analyses and validation. 
We found that the expression level of endothelial-enriched genes were largely 
unaltered in kdrl+ cells of homozygous grc mutant embryos when compared to those 
seen in wild-type.  In contrast, the majority of these genes were down-regulated in 
the same population from homozygous clo mutant embryos (Figure 2A), suggesting 
that a locus affected by grc mutation may be only required in a subset of endothelial 
cells.  A small subset of endothelial-enriched genes was markedly down-regulated in 
both homozygous grc and clo mutant embryos.  For instance, we found that an 
arterial specific marker, tbx20 [30], as well as a putative zebrafish ortholog of 
mammalian Platelet Endothelial Cell Adhesion Molecule (PECAM), 
ENSDART00000084729, was significantly down-regulated in kdrl+ cells isolated from 
both homozygous grc and clo mutant embryos (Figure 2A).  Interestingly, we found 
that genes up-regulated (q=0) in all three mutants were found to be characteristic of 
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other mesodermal, non-endothelial lineages such as somite, blood, or kidney (Figure 
2B).  For instance, we found protein kinase c delta a (prkcda), which are expressed 
in blood and somitic lineages [31], and adenosine kinase a (adka), which are 
expressed in blood and pronephric lineages [32], was up-regulated in kdrl+ cells from 
avascular mutant embryos.  Taken together, our microarray data suggest that kdrl+ 
cells found in avascular mutant embryos may retain more mesodermal 
characteristics than those from wild-type embryos. 
To better understand molecular characteristics of the kdrl+ cells in avascular 
mutant embryos, we analyzed the expression level of transcription factors in our 
microarray data (Figure 2C).  We found that total of 43 transcription factors were up-
regulated in kdrl+ cells from avascular mutant embryos (Figure 2D) at q=0. Among 
these transcription factors, we further analyze the function of sox11b, a zebrafish 
ortholog of SRY-related HMG Box 11 (SOX11) [28], which is a member of SOXC 
subgroup [33].  Previously, it has been shown that Sox11b is essential for mediating 
retinal development and neuronal regeneration in zebrafish [28].  However, its role in 
endothelial cells and vascular development has not been investigated.  Up-
regulation of sox11b in kdrl+ cells in avascular mutant embryos was confirmed by 
quantitative RT-PCR (Figure 3A). 
During development, sox11b is highly expressed in multiple tissues including 
neurons, somites, and retina as previously proposed.  In addition, approximately at 
24 hpf, sox11b expression was detectable in developing posterior axial vessels in 
wild-type embryos (Figure 3B).  A similar expression pattern was seen in avascular 
mutants (Data not shown).  To analyze temporal changes in sox11b expression 
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within endothelial cells, kdrl+ cells were isolated from wild-type embryos and 
quantitative RT-PCR was performed.  We found that sox11b expression can be 
detected as early as 18 hpf, and the level of expression gradually increases until 72 
hpf within endothelial cells, consistent with our in situ hybridization result (Figure 
3C).  Interestingly, the expression of sox11b appears to be induced by Bone 
Morphogenetic Protein (Bmp) signaling, as over-expression of Noggin3, an 
endogenous antagonist of Bmp signaling, led to a substantially decrease on the level 
of sox11b transcript level (Figure 3D).  Considering that Bmp signaling functions as 
a context-dependent pro-angiogenic cue [18,34], it is possible that Sox11b may 
function as one of the effectors in this process. 
To better assess the function of Sox11b during vascular development, we 
attenuated the activity of Sox11b by injecting morpholino (MO) anti-sense 
oligonucleotide as previously reported [35].  Embryos injected with sox11b MO 
displayed discernible defects in vascular development, compared to control MO 
injected embryo (Figure 4A).  At 32-34 hpf, the length of intersegmental vessels, 
which sprout from the dorsal aorta at this stage [36], was substantially reduced in 
sox11b MO injected embryos (Figure 4B).  While control MO injected embryos had 
an average length of 89.82±1.92μm (N=139 ISVs), sox11b MO injected embryos 
intersegmental vessels were significantly shorter, 82.67±2.46μm (N=156 ISVs, N=8 
embryos; Figure 4B, 4C and E), indicating that the function of Sox11b is essential for 
the morphogenesis of sprouting intersegmental vessels during development.  Since 
a mammalian ortholog of Sox11b, SOX11 is known to promote transcription of key 
cell cycle regulators including Cyclin-dependent kinase CDKN2B and Histones [37], 
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as well as arrays of Actin binding proteins which modulate cell motility [37], it is 
possible down-regulation of Sox11b by MO injection led to a decreased endothelial 
proliferation and/or migration. 
Since intersegmental vessels at 24 hpf are arterial in nature [36], we 
investigated whether sox11b preferentially influences migration of arterial endothelial 
cells, by analyzing the effects of sox11b knock-down on sprouting angiogenesis of 
caudal vein plexus (CVP).  Previously, we reported that the CVP undergoes 
morphogenetic changes starting at 30 hpf by forming extensive ventral sprouts [18].  
In sox11b MO injected embryos, the number of angiogenic sprouts was drastically 
reduced compared to control MO injected embryos at 32 hpf (1.85±0.56 in sox11b 
MO injected embryos and 11.4 ±1.0 in control MO injected embryos; Figure 4A, 
white arrowheads and 4D).  Morphologically, the CVP in sox11b MO injected 
embryos failed to undergo proper morphogenesis to generate the dorsal vein and 
the ventral vein as in wild-type embryos (Figure 4G), reflecting the attenuated 
sprouting angiogenesis in these embryos. 
Conclusion  
Our results indicate that kdrl+ cells in avascular mutant embryos express a 
unique transcriptional profile that allow them to circumvent the initial failure of 
endothelial specification, which led to the formation of rudimentary vascular structure 
in these embryos.  We found that a number of transcription factors were selectively 
up-regulated in the kdrl+ cells of avascular mutant embryos, indicating that these 
transcription factors may guide an alternative mechanism to generate the endothelial 
lineage.  We analyzed the function of one of the transcription factors isolated from 
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our microarray, sox11b, and found that sox11b plays an important role in early 
morphogenesis of the vasculature by mediating sprouting angiogenesis. Taken 
together, our data provides a compelling evidence of developmental heterogeneity of 
the endothelial lineage. 
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FIGURES: 
 
 
 
 
 
Figure 2.1: Avascular mutant embryos generate endothelial cells at later 
stages 
(a) Gross morphology of 72 hpf wild-type (left), groom of cloche (grc) 
(middle), and cloche (clo) embryos in Tg(kdrl:eGFP) background.  Both bright-field 
(top rows) and epifluorescent (bottom rows) images are shown. Scale bar=250μm. 
(b) Transverse section of 72 hpf embryos taken from the area marked by dashed 
line in (a).  GFP+ endothelial cells are shown in green and nuclei stained with DAPI 
are shown in white.  Scale bar=50μm.
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Figure 2.2:  Expression profile of kdrl+ cells isolated from avascular mutant 
embryos. 
 (a) Schematic diagram for molecular profiling.  (b) Expression profile of known 
lineage specific markers in microarray (*: q<0.05).  (c) Characteristics of genes 
which are up-regulated in endothelial cells in all three avascular mutant embryos. A 
total of 32 genes were shown to be up-regulated.  (d) Expression profiles of putative 
transcription factors of which function have not previously implicated in the 
endothelial lineage.  These genes were up in grc and clo (q=0), but not down-
regulated in cas. 
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Figure 2.3:  sox11b expression is elevated in kdrl+ cells isolated from 
avascular mutant embryos. 
(a) Quantitative RT-PCR analyses confirmed the up-regulated expression of 
sox11b in endothelial cells of avascular mutant embryos.  Two additional 
transcription factor, klf5l and zfhx4, were used as positive controls.  (b) Temporal 
expression change of sox11b expression in endothelial cells.  (c) in situ hybridization 
of sox11b at 24 hpf wild-type embryo.  In addition to neural tube and somite, axial 
vessels express sox11b.  Anterior somite, axial vessel, and caudal vein are indicated 
by the yellow arrow, asterisk, and black arrow, respectively.  (d) Effects of BMP 
signaling on sox11b expression.  A decreased activity of BMP signaling significantly 
reduces the expression of sox11b in endothelial cells. 
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Figure 2.4:  sox11b regulates sprouting angiogenesis during development. 
(a) Epifluorescent micrographs of control (top) or sox11b (bottom) morpholino 
(MO) injected embryos. Trunk regions posterior to the end of yolk extension are 
shown. White arrowheads indicate ventral sprouts. Scale bar=250μm.  (b) 
Intersegmental vessel and caudal vein defect in sox11b MO injected embryos at 34 
hpf. Scale bar=100μm.  (c) Truncation of ISVs and plexus defects at 48 hpf. Scale 
bar=250μm.  (d) Decreased venous sprouting angiogenesis in the caudal vein 
plexus (CVP) of sox11b MO injected embryos at 32  hpf is quantified.  (e) The effect 
of sox11b MO on the length of intersegmental vessels is quantified (N=139, N=10 
embryos). 
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CHAPTER 3 
A Paired Box Homeodomain Transcription Factor pax9 as a Novel Regulator 
for the Migration of Endothelial Cells during Vascular Morphogenesis 
 
Summary 
Multiple populations of endothelial cells exist during development and into 
adulthood.  Two avascular zebrafish mutants, clo and grc, which retain small 
populations of kdrl+ cells and undergo vascular morphogenesis allow for the study of 
endothelium which is able to specify in the absence of clo or etv2.  Using clo and grc 
as models for endothelial heterogeneity, we performed lineage tracing from shield 
stage and found an increase of kdrl- unspecified mesoderm, indicating that much of 
the mesoderm fated to become angioblasts fails to specify.  Additionally, we 
determined that a large portion of early kdrl+ cells in these mutants are specified from 
tailbud, as opposed to lateral plate mesoderm.  Given the unique developmental 
source of endothelium in avascular mutants, we focused on a transcription factor 
previously indicated to be up-regulated in avascular mutant kdrl+ cells, pax9.  We 
found that pax9 is highly enriched in developing zebrafish vasculature and controls 
vascular morphogenesis.  We also found that pax9 controls scratch closure in 
HUVEC cell culture, indicating that its role in vascular morphogenesis is likely 
conserved across vertebrates. 
39 
 
Highlights 
 Avascular mutants undergo endothelial specification at later stages. 
 Tailbud mesoderm largely contributes to vascular recovery. 
 pax9 is up-regulated in avascular mutant kdrl+ cells.  
 Modulation of pax9 controls vascular morphogenesis. 
 
Results and Discussion 
 In order to define alternative mechanisms of endothelial specification and 
organization, we decided to use avascular mutants as a model for endothelial 
heterogeneity.  We have previously isolated an avascular mutant, groom of 
cloches635 (grc635) from a large scale forward genetic screen [1].  At early stages, the 
vascular phenotype of grc is comparable to that of cloche (clo), an avascular mutant 
that lacks both endothelial and hematopoietic lineages (Fig. 3.1A) [2].  Homozygous 
grc mutant embryos completely lack the expression of endothelial specific markers 
including kdrl, dab2, and cdh5 at early developmental stages, indicating that the 
endothelial lineage failed to be specified or not maintained (Fig. 3.5).  However, 
approximately at 18 hours post-fertilization (hpf), a small group of kdrl+ cells can be 
detected in the posterior region of homozygous grc mutant embryos, which 
subsequently expanded.  At 72 hpf, a rudimentary vascular structure can be 
detected in the majority of homozygous grc mutant embryos (Fig. 3.2A), and a small 
fraction (less than 5 percent) of these embryos survive to the adulthood.  Similarly, 
we found that homozygous clo mutant embryos do possess kdrl+ cells at later stages 
(Fig. 3.2A), indicating that the function of grc and clo may be required only during 
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early development, or may regulate differentiation of subsets of the endothelial 
lineage. 
To determine whether the mutations in grc or clo locus shift the ratio of 
different mesoderm-derived lineages, we first evaluated whether mutation in grc 
locus led to an expansion of other related mesodermal lineages by performing a 
lineage tracing using caged fluorescein-conjugated Dextran as previously reported 
(Fig. 3.1B) [3].  Approximately two cells within the developing gastrula were 
activated with an ultraviolet laser at 5.5 hours post fertilization (hpf) when cells are 
restricted to a single lineage [4], and at 24-26 hpf, the distribution of the descendants 
from uncaged cells were analyzed.  Compared to the wild-type embryos, 
homozygous grc or clo mutant embryos contain significantly increased number of 
mesodermal descendents that do not belong to an identifiable lineage in the midline 
and tail of the embryo, which preferentially localizes to the posterior, caudal to the 
yolk extension (Fig. 3.1D).  Based on this observation, it was tempting to speculate 
that the mesodermal cells capable of generating the endothelial lineage fail to 
undergo further differentiation in the absence of grc or clo function, and remain 
undifferentiated and incorporated into the tailbud mesoderm.  Consistent with earlier 
fate mapping studies, we found that cells within the first five tiers of wild-type 
gastrula generate somite, endothelium, blood, and pronephros, in addition to a small 
number of undifferentiated cells in 30 hpf embryos (Fig. 3.1C).  Compared to the 
wild-type embryos where mesodermal cells give rise to the endothelial and 
hematopoietic lineages (33% for endothelial lineage and 5% for hematopoietic 
lineage, respectively), homozygous clo embryos lack both endothelial and 
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hematopoietic lineages, reflecting previously reported defects (Fig. 3.1D) [2].  
Similarly, homozygous grc embryos selectively lack the endothelial lineage (Fig. 
1D).  In both cases, we observed substantial increase in kdrl- mesodermal cells in 
the midline and tail of the vascular mutant embryos (33% in clo and 17% in grc) (Fig. 
3.1D).  Therefore, it appears that the progenitors for the endothelial lineage remain 
undifferentiated in these avascular mutant embryos.   
To better understand the molecular mechanisms underlying the emergence of 
the endothelial lineage at later stage, we isolated the locus affected by grc mutation 
by whole genome sequencing.  Sequencing analyses revealed that the grc mutation 
was significantly associated with Leu248 to Pro248 changes in etv2, also known as 
etsrp, which is an essential transcription factor for the endothelial lineage [5, 6] (Fig. 
3.6).  Previously, mutation in etv2 causing a premature stop has been identified in 
zebrafish, and morpholino (MO) knock-down of etv2 has shown to cause a drastic 
reduction in the number of endothelial cells [7].  The phenotype of homozygous grc 
mutant embryos was wholly consistent with these findings.  Additionally, we found 
etv2 morphants displayed severe intersegmental vessel growth deficiencies (Data 
not shown, N=21). 
Considering that both homozygous grc and clo mutant embryos generate 
endothelial cells at later stages, it appears that these avascular mutant embryos 
retain the ability to generate the endothelial lineage.  We noted that the majority of 
the kdrl+ cells in avascular mutants are located in the posterior of the embryo at 24 
hpf (Fig. 3.2A).  Since it has been reported that tailbud can contribute to the 
endothelial lineage in Wnt-dependent manner [8], we examined whether endothelial 
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cells found in later stages of avascular mutant embryos are derived from the tailbud 
by laser-activation of uncaged fluorescein-conjugated Dextran at 14 hpf.  While 
approximately 63% percent of endothelial cells within the posterior region (posterior 
to the cloaca) of wild-type embryos were the descendents of tailbud mesoderm, 
virtually all kdrl+ endothelial cells found in either homozygous grc or clo embryos 
were originated from the tailbud (93% in clo and 93% in grc) (Fig. 3.2E).  The lower 
percentage in wild-type was expected as there is observable mixing of endothelial 
cells in intact vasculature.  Therefore, it appears that the tailbud mesoderm is the 
predominant source of endothelial cells in homozygous grc and clo embryos and a 
significant source in wild-type.  Taken together, our observation raised an intriguing 
possibility that the emergence of endothelial cells derived from the tailbud may not 
require the activity of either etv2 or clo, alluding that the molecular mechanisms that 
induce the endothelial lineage from the tailbud and the lateral plate mesoderm are 
likely to be distinct. 
To ascertain whether kdrl+ cells from wild-type or avascular mutant embryos 
have differential transcriptional profiles, we previously performed microarray 
analyses (Chapter 2).  Using flow cytometry, kdrl+ cells from 18.5 hpf wild-type and 
avascular mutant embryos were isolated and mRNA was extracted.  We found that 
the expression of related mesodermal lineage markers was significantly up-
regulated in kdrl+ cells from avascular mutant embryos (Fig. 2.2C), and further 
validated alteration in the expression level of four genes, including pax9, by 
quantitative RT-PCR (Fig. 2.3A and Fig. 3.3A).  A paired box homeodomain 
transcription factor, pax9, was one of the genes whose expression was significantly 
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up-regulated in avascular mutant embryos.  Although pax9 has previously been 
implicated as the key transcription factor for odontogenesis [9, 10] and development 
of pharyngeal pouch-derived organs in mouse [11], its role in endothelial biology is 
largely unknown.  To further delineate the role of pax9 during vascular development, 
we first examined the expression pattern of pax9 in wild-type and avascular mutant 
embryos.  In flow sorted endothelial cells, consistent with the microarray data, the 
expression of pax9 within endothelial cells appears to be substantially elevated in 
homozygous grc or clo embryos compared to wild-type embryos (Fig. 3.3A).  
Moreover, in wild-type, the expression of pax9 became stronger in endothelial cells 
isolated from the later stage embryos, and is more pronounced in endothelial cells 
isolated from the trunk region (Fig. 3.7).  In wild-type embryos, strong endothelial 
expression of pax9 could be detected at 24 hpf. At 36 hpf, the expression is 
gradually restricted to the endothelial cells in the trunk and tail region, indicating its 
role in endothelial cells at later stages (Fig. 3.3B).  In homozygous grc and clo 
mutant embryos, strong pax9 expression was present in the midline vascular area 
(Fig. 3.3C).  
To examine the function of pax9 during vascular development, we attenuated 
the activity of pax9 by morpholino (MO)-mediated knock down in wild-type embryos.  
While the number of kdrl+ cells, as well as proliferation and apoptosis of endothelial 
cells were unaltered (Fig. 3.8), the complexity of the vascular network in pax9 MO-
injected embryos was drastically reduced compared to control MO-injected embryos 
(Fig. 3.4A and B).  Interestingly, we did not find any obvious differences in the total 
number of endothelial cells from pax9 MO-injected or control MO-injected embryos 
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(Fig. 3.4B, top left).  However, the number and average length of intersegmental 
vessels (ISVs), as well as the number of branch points were substantially reduced in 
pax9 MO injected embryos, compared to control MO injected embryos (Fig. 3.4B, 
Panels 2-4), indicating that pax9 may affect migration and morphogenesis of 
endothelial cells.  Similarly, inhibition of pax9 in homozygous grc or clo mutant 
embryos caused similar phenotype (Fig. 3.4A and B).  To determine whether the 
effect of pax9 on endothelial morphogenesis was cell autonomous, we performed 
classic transplantation experiments.  A small number of cells from control or pax9 
MO-injected donors were transplanted to wild-type host at gastrula stages.  While 
transplanted cells contributed to the endothelial lineage in all cases, we found that 
cells from pax9 MO-injected donor in wild-type recipient were selectively excluded 
from secondary angiogenic vessels such as intersegmental vessels (Fig. 3.3D and 
E).  Therefore, it appears that pax9 cell-autonomously influences the migration of 
endothelial cells and does not regulate the specification and differentiation of the 
endothelial lineage. 
Considering that inhibition of pax9 attenuated the formation of ISVs, but did 
not affect cell proliferation, apoptosis, and differentiation of endothelial cells, it is 
possible that pax9 may influence the migration of endothelial cells during 
development.  Our observation that kdrl+ cells in homozygous grc or clo mutant 
embryos are more migratory than wild-type (Fig. 3.1A and B), and express higher 
level of pax9, further support this idea.  To explore this possibility in detail, we first 
examined the migratory behaviors of endothelial cells in 24 hpf zebrafish embryos by 
tracking the movement of individual endothelial nuclei for 6 hours.  We found that 
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endothelial cells from the pax9 MO-injected embryos moved significantly less than 
control MO-injected embryos, which resulted in delay in ISV formation (Fig. 4B., 
bottom left).  To further examine the effects of pax9 in endothelial migration, we 
knock-down pax9 in human umbilical vein endothelial cells (HUVECs) and perform 
migration assays.  In the wound healing scratch assay, pax9 siRNA-treated 
HUVECs showed substantially decreased migration compared to control siRNA-
treated HUVECs (Fig. 3.4C and D), indicating that the function of pax9 promoting 
endothelial migration is conserved among vertebrates.   
Since it has been reported that Wnt signaling promotes the differentiation of 
skeletal muscle at the expense of endothelial cells in tailbud of zebrafish[8], it is 
tempting to speculate that Wnt signaling may inhibit pax9 expression within tailbud 
mesoderm with angiogenic potential, thereby regulate differentiation of endothelial 
cells.  To test this notion, we examined the effects of Wnt signaling on pax9 
expression.  In 6-bromoindirubin-3'-oxime (BIO)-treated embryos, which up-
regulates Wnt activity [12], the expression of pax9 was substantially decreased 
compared to DMSO-treated embryos (Fig. 9).  Since manipulation of Vascular 
Endothelial Growth Factor (VEGF) and Bone Morphogenetic Protein (BMP) signaling 
did not alter the expression level of pax9 (Fig. 3.9), it appears that the effects of Wnt 
signaling on pax9 expression may be specific.  Taken together, our data show that 
pax9 is novel regulator of endothelial cell migration during development of which 
function is evolutionarily conserved.  Moreover, our data suggest that pax9 may be a 
novel target in diverse human pathological conditions with vascular components.   
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Experimental Methods. 
Zebrafish husbandry and morpholino injection. 
Zebrafish (d. rerio) embryos were reared at 28.5°C and, when necessary, 
synchronized for short periods at 25°C or 32°C.  Morpholinos were injected at the 
one or two-cell stage at a volume of 4.6nL using a picospritzer gas-pressure injector.  
All morpholinos were injected in 5mM HEPES and 0.05% Phenol Red.  Pax9 
morpholino (Sequence: 5′-CCAAAGGCTGGCTCTAGTTATGCAG-3′) was injected at 
a concentration of 600μM.  Efficacy of this splice-blocking morpholino was measured 
using RT-PCR (Fig 3.10). 
Cloning of grc. 
grc was isolated from a previously published forward genetic screen using the 
Tg(kdrl:eGFP) transgene [1].  Homozygous mutants were identified by the absence 
of GFP vasculature and the retention of GFP fluorescence in the endocardium and 
pharyngeal endoderm.  Bulked segregant analysis was performed using simple 
sequence length polymorphism (SSLP) markers as previously described [13] and 
the genetic lesion was found to be located on Chromosome 16.  Further SSLP 
mapping refined the region to approximately 30kB on Chromosome 16.  Since this 
region contained a gap, we utilized High Throughput Sequencing (paired end 
Illumina Sequencing technology) of the transcriptome and genome of pooled 
homozygotes in order to define the missing sequence and determine the mutation 
underlying grc [14].  Initially runs-of-homozygosity were scored and found to agree 
with the previously indicated region on Chromosome 16.  Only one single nucleotide 
polymorphism (SNP) was exclusively found in the grc sequence library.  This 
47 
 
mutation was an A to G substitution which results in a leucine to proline amino acid 
change.  This mutation was then confirmed using a derived cleavage of amplified 
polymorphisms (DCAPS) assay [15].   
Validation of up-regulation of pax9. 
For qRT-PCR, RNA was extracted using the QIagen RNeasy mini kit and 
accompanying protocol with carrier RNA.  The iScript cDNA synthesis kit (Bio-Rad) 
was used to reverse transcribe entire RNA extracts, immediately after RNA 
extraction.  cDNA samples were then diluted to a volume of 300μl.  Using 2X Power 
syber mastermix (Applied Biosystems), 640nM of each primer, and 8μl of cDNA in a 
25μl reaction, amplification of transcript amplicon was monitored on a Bio-Rad cfx96 
system.  Gene expression was normalized to either 18S rRNA or β-actin 
housekeeping genes.  Melting curve analysis was performed on all reactions.  Ct 
versus cDNA concentration plots were also used to determine that there was a linear 
ratio of amplification of housekeeping genes to gene-of-interest at a particular cDNA 
concentration.  Data was analyzed using the 2-∆∆cT method [16].  At least three 
biological replicates of three technical replicates were performed for each condition.  
Primers:  
Name Forward Reverse 
18S rRNA cacttgtccctctaagaagttgca ggttgattccgataacgaacga 
β-actin tggcccctagcacaatgaag gcctccgatccagacagacagagtat
pax9 tcaagagcatgagtgccacacg agtcatagagctgaagccaccag 
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Lineage tracing. 
0.2% w/v (2ul of stock in 10ul injection mix) caged fluorescein dextran with 
phenol red and HEPES was injected at a 4.6nL volume at the one to two cell stage.  
For shield stage uncaging, embryos were mounted laterally in 3% methylcellulose in 
30% Danieau in a glass bottom dish.  A two-photon laser on a Zeiss 710 scope was 
used.  The laser line was set to 735nM.  The bleach function was set to 30 pulses.  
For tailbud uncaging, embryos were mounted in a glass-bottom dish in 1% low-melt 
agarose and exposed to UV light using the scan function of the DAPI channel on a 
Leica SP5.  ROIs were selected accordingly.  Embryos were observed at 24 hpf.  
Further fixing, sectioning and staining were performed using established 
protocols[17] and the following antibodies: chick anti-GFP (AB-CAM), goat anti-
fluorescein (Invitrogen), donkey anti-goat 594 (Jackson Immunoresearch), donkey 
anti-chick 488 (Jackson Immunoresearch). 
In situ hybridization. 
In situ hybridization was performed following established protocols [18].  pax9 
probe was generated using agarose-gel purified PCR fragments (PCR Primers: 
“PAX9ISHF”, 5′-cgctatcacatccgtctcg-3′ and “PAX9ISHR”, 5′tgcttgttaccccacactga-3′), 
which were ligated into the PGEM-T easy vector *(Promega).  Transformed colonies 
were selected and sequenced.  The final amplified vector was linearized and 
transcribed using SP6 polymerase (Roche T7/SP6 DIG-UTP labeling kit).  
Transverse cryostat sectioning of in situ hybridized embryos was performed as 
described[19] and counterstained with Nuclear fast red. 
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Mitosis/Apoptosis assays. 
The Roche in situ cell death detection kit was used with the associated 
protocol to detect apoptotic kdrl+ cells in 250μM vibratome sections of zebrafish 
embryos.  Rabbit anti-phospho histone H3 (Ser 10) antibody (Millipore) and Donkey 
anti-rabbit 568 (Invitrogen) secondary antibodies were used to stain mitotic kdrl+ 
cells in vibratome sections. 
Transplantation 
Transplantation was performed as previously described [20].  Embryos were 
observed at 24 hpf and image on a Leica SP5 confocal microscope for cellular 
resolution. 
HUVEC Cell culture and scratch assay 
HUVECs were cultured on 0.1% gelatin-coated plates in complete endothelial 
cell growth media containing supplements (Lonza, CC-3162) and 100 unit/ml 
penicillin-streptomycin.  Cells between passages 3 and 7 were used for analyses.   
HUVECs were transfected with Human PAX9 or nontargeted control siRNA (100nM, 
Dharmacon, Lafayette, CO, USA) using lipofactamine 2000 (Invitrogen, Carlsbad, 
CA, USA).  Cells were used for assays at 48 hours after transfection.  Expression 
level of PAX9 (Cell signaling; 8739, 1:1,000) were determined by Western blotting. 
HUVECs were transfected with the indicated siRNAs.  At 32 hours after transfection, 
cells were serum-starved overnight.  The cell monolayer was scratched with a 200 μl 
pipette tip to create a cell-free zone.  Thereafter, cells were gently washed twice with 
the medium and incubated for 6h.  The cells were imaged using inverted 
microscope. 
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The wound areas were measured by ImageJ, normalized and presented as the 
percentage of wound measured at time 0.  At least seven fields were analyzed for 
each scratch and each sample was performed in duplicate.  The closure distance 
was generated by averaging 4 measurements per picture at 0h and 6hr. 
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Figures: 
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Figure 3.1:  Failure of the majority of endothelial cells to specify early on in 
avascular mutants.    
(A) Wild-type, grc, and clo embryos at 18.5 hpf.  (B) Schematic for shield-
stage lineage tracing by caged-fluorescein dextran.  (C) Spatial origin of somite, 
endothelium (kdrl+), and unspecified cell-types in wild-type, grc, and clo.  (D) 
Percentage of mesodermal cells giving rise to a particular lineage wild-type, grc, and 
clo.  WT N=245, grc N=70, clo N=66 embryos. 
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Figure 3.2 (cont.) 
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Figure 3.2:  Recovery of the endothelial lineage via tailbud-dervied 
angioblasts.   
(A) wild-type, grc, and clo embryos at 24 and 48 hpf respectively.  White 
arrowheads indicate kdrl+ cells.  (B) Flow cytometry analysis of wild-type, grc, and 
clo at 18.5 hpf and 30 hpf.  Three biological replicates consisting of 15 dissociated 
embryos were performed.  (C) Schematic for tailbud lineage tracing at 12 somite 
stage.  (D) Representative images of wild-type, grc, and clo transverse tail sections 
stained for GFP (green) and Uncaged fluorescein dextran (red), merged with DAPI 
(Blue), respectively.  (E) Estimation of the percentage of kdrl+ cells derived from 
tailbud.  N=22,17, and 7 embryos for WT, grc, and clo, respectively   
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Figure 3.3:  pax9 expression in the vasculature and cell-autonomous function 
in vascular morphogenesis.   
(A) qRT-PCR for pax9 expression in FACS sorted cells at 18.5 hpf.  Three 
biological replicates and three technical replicates were done.  (B) in situ 
hybridization pattern of pax9  at 18.5, 24 and 36 hpf (red asterisk indicates ISV, 
black arrow indicates dorsal aorta, black asterisk indicates caudal vein).  (C) 
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Transverse sections of in situ hybridized embryos at 24 hpf (black arrows indicate 
expression in the vascular area (VA)).  Images are 100μM wide.  (D) Representative 
images for transplantation of control (top) or pax9 morphant donor cells and 
schematics illustrating their contribution to different regions.  (E) Quantification of 
wild-type pax9 morphant to wild-type transplantation experiments (N=8 each).  Scale 
bars = 50μm  
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Figure 3.4 (cont.) 
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Figure 3.4 (cont.) 
 
 
 
 
 
 
 
 
Figure 3.4:  Conservation of the role of pax9 in zebrafish and human 
endothelium.   
(A) pax9 morpholino severely reduces the number of ISVs, length, and 
branching morphogenesis in avascular mutants, while not decreasing the number of 
cells and (B) quantification.  N=43, 50, and 25 for WT, grc, and clo, respectively. (C) 
Representative images from HUVEC cell scratch assay (scratch area highlighted in 
yellow) and (D) quantification.  N=56 measurements, 14 regions per condition, 2 
biological replicates.  Scale bars in panels A and B are 250 μM and 20 μM, 
respectively.  
4C. 
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Figure 3.5:  Phenotypic analysis: expression of hemato-vascular genes in grc.   
 
(A) in situ hybridization shows pu.1 expression in grc embryos is mildly 
changed in the posterior blood island, as was previously published.[5] gata1 
expression was not changed.  cdh5 expression was absent in grc.  The venous 
marker, dab2, was absent in grc embryos.  (N>5 embryos for each condition) (B) 
Whole embryo expression of pu.1 and gata1 confirmed the findings in panel A.  
Additionally scl and lmo2 are down-regulated in grc embryos by qRT-PCR when 
normalized to 18S rRNA or β-actin.  Asterisk indicates a p-value of less than 0.05.  
Averages are the result of three biological replicates with three technical replicates 
each.  
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Figure 3.6:  Cloning of grc mutation.  
  
Using high-throughput transcriptome and genome sequencing with a large 
reference library, we isolated a single-nucleotide polymorphism not found in any 
other reference sequence.  There were no other unreported SNPs in the run of 
homozygosity on Chromosome 16.  The A to G substitution leads to a Leucine to 
Proline mutation in the Etv2 peptide.  Using the program, Polyphen, this mutation 
was predicted to damage the overall protein structure.   
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Figure 3.7:  Expression profiling of pax9 within endothelial cells.  
qRT-PCR results showing that pax9 is actually expressed at lower levels in 
the developing zebrafish tail vasculature in the tail compared to trunk, when 
normalized to 18S rRNA, at 24 and 72 hpf, respectively.  Average of three biological 
replicates, three technical replicates.  Error bars indicate SEM.  P-value is from a 
two-tailed homoscedastic ttest.  
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Figure 3.8:  pax9 does not affect vascular morphogenesis via apoptosis or 
proliferation in mutants.  
(A) Phospho histone-H3 antibody staining in the developing vasculature did 
not reveal differences between mutant when pax9 was knocked-down.  Pax9 down-
regulation in wild-type did show a significant reduction in cell-cycle entry of about 4-
fold.  N > 23 samples for each condition.  (B) No significant differences in apoptosis 
of kdrl+ cells was noted by TUNEL assay.  Sample size for clo was low, but we 
noted a higher level of apoptosis in all tissues in homozygous clo embryos.  Sample 
sizes for WT and grc at 24 hpf were N=60, N=18 respectively and at 72 hpf and 
N=96 N=32. 
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Figure 3.9:  pax9 expression is decreased by WNT agonist BIO within 
endothelial cells.  
Agonism of WNT signaling by treatment with BIO from 20 hpf to 30 hpf 
reduced expression of pax9 within endothelial cells by around five-fold.  The FGF 
inhibitor, SU5402, also showed a significant decrease in expression of pax9 by 
about one-third.  Averages are of three biological replicates and three technical 
replicates each.  Other drugs/treatments tested were Notch inhibitor (DAPT), 
BMPR2 inhibitor (DMH1), inducible BMP antagonist (Tg(Hsp70l:Noggin3)), and 
inducible BMP agonist (Tg(Hsp70l:Bmp2b)), which showed no effect.  Treatment 
with VEGF inhibitor (SU5416) actually increased pax9 expression by about two-fold 
within endothelial cells (Data Not Shown. 3 biological replicates, three technical 
replicates).  Heat shock treatments were carried out at 26 hpf and all FACS sorts 
were carried out at 32 hpf. 
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Figure 3.10: Efficacy of pax9 splice-blocking morpholinos.   
Agarose gel showing Pax9 RT-PCR.  The full coding sequence of pax9 was 
amplified from cDNA libraries from pools of control morpholinos injected embryos 
(lane 2) or pax9 morpholino injected embryos (Lane 3) using primers recognizing the 
first and last coding exons.  Lane 1 is Invitrogen 1kB plus ladder.  Full-length pax9 
amplicon is 1205bp and a minor isoform of 1065bp is also seen (lane 2). 
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CHAPTER 4 
Conclusions 
 
This thesis elucidates an alternative developmental pathway that 
generates the endothelial lineage and illustrates the role of two genes, pax9 and 
sox11b, in this process.  My research is one of the first attempts that dissect the 
heterogeneous origin of the endothelial cells at molecular level.  Therefore, 
findings of my thesis research represent important contributions to the field of 
vascular biology and will serve as building blocks for future studies into the role 
of these genes in endothelial biology.  This discussion highlights the key points 
found in each chapter as well as discusses potential future endeavors which may 
prove to expand our knowledge of the mechanisms of vascular development. 
 
Chapter 2 
Key Points 
1. Vascular development proceeds in the absence of clo/etv2 function. 
2. The clo/grc early kdrl+ lineages have a unique transcriptional profile.  
3. Modulation of sox11b levels by morpholino injection perturbs wild-type 
angiogenesis. 
 
71 
 
Conclusion 
Together, the findings described in Chapter 2 of the first chapter suggest 
that vasculogenesis proceeds in mutant backgrounds which lack gene function 
necessary for the specification of the majority of the endothelial lineage. 
Furthermore, the novel transcriptional pathways functioning in mutant endothelial 
cells which are specified in these backgrounds is distinct from that in wild-type 
and definable.   
Using transgenic avascular mutant zebrafish, we were able to highlight the 
earliest detectable emergence of the endothelial lineage in the attenuated mutant 
background.  By microarray analyses, we were able to describe the 
transcriptional profile that is distinct in these cells.  At initial review, many of the 
genes upregulated in early avascular mutant endothelium were characteristic of 
other mesodermal lineage, indicating a novel mechanism of differentiation and a 
unique identity from early wild-type endothelial cells. 
Validation of the microarray by real-time qRT-PCR yielded at least four 
novel transcription factors upregulated in mutant angioblasts.  Perturbation of 
sox11b by morpholino knockdown showed that this gene is necessary for proper 
vascular development.  Furthermore, this morpholino experiment demonstrated 
that the transcriptional profile of avascular mutants could be used to elucidate 
new genes involved in vascular patterning that were not previously isolated by 
the study of wild-type animals.   
Chapter 2 represents a validation of our attenuated model system.  
Further, it demonstrates that in the absence of clo or etv2, endothelial cells can 
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be specified.  Additionally, endothelial cells specified despite this deficiency have 
a unique transcriptional profile that has allowed for the discovery of the 
involvement of sox11b in vascular morphogenesis.   
 
Future Directions 
 The apparent delay in sprouting angiogenesis seen in sox11b morphants, 
while implicating this gene in vascular development, does not specify the mode 
of action of this gene.  As such, I believe that by performing transplantation to 
determine if sox11b functions cell-autonomously or by cell-cell signaling, since 
sox11b is also expressed in the neighboring anterior somites.  Our study did not 
rule out the possibility that sox11b expression in the surrounding somites 
provides signals that direct the vascular patterning of adjacent angioblasts and 
endothelial cells.  Furthermore, cell-cycle analysis by phospho-histone H3 
staining would be informative.  Lastly, investigation into the two other validated 
genes, zfhx4 and klf5l would reveal whether these genes have overlapping 
function.  These analyses would greatly expand the role of these genes in the 
emergence of endothelial cells during avascular mutant development.   
Given the expression in anterior somite, sox11b expression modulation 
might be acting to disrupt some signaling between these tissues.  However, there 
are several indications that sox11b functions cell-autonomously.  Firstly, sox11b 
is a transcription factor, which means it functions within the nucleus of the cell in 
which it is expressed.  The microarray analyses and accompanying validation 
were measuring gene expression within Tg(kdrl:eGFP)+ cells.  By utilizing 
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isochronic blastula cell transplantation, it could be determined if sox11b 
morpholino has any measurable effect on endothelial cell behavior in a wild-type 
host environment. 
Since previous reports have indicated that sox11 has a role in cell-cycle 
progression [1-3], the phenotype seen in morphants could be due to a delay in 
proliferation of endothelial cells and subsequent recovery in a microenvironment 
lacking the necessary migratory cues.  Because of this concern, I would suggest 
performing phospho-histone H3 staining to see if fewer endothelial cells are 
undergoing mitosis, at the 24 hpf time point.  Additionally, flow cytometry 
analyses of the GFP+ cells with propidium iodide staining would help to quantify 
cell cycle phase in control versus sox11b morphants. 
Two additional genes were validated as up-regulated by qRT-PCR in the 
kdrl+ lineage in early avascular mutant embryos, klf5l and zfhx4.  These genes 
have not been implicated in vascular development and have little or no 
characterized role in other tissues.  I would suggest morpholino-mediated 
knockdown of these genes to answer two questions.  Of course, knockdown 
could show whether these genes play a role in vascular development at any time 
point.  More importantly, this analysis would address whether these three genes 
function in a similar manner and by extension, belong to a functional class of 
transcription factors.  
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Chapter 3 
Key Points 
    1. The mesodermal lineage defaults to unspecified fate in avascular mutants. 
    2. Avascular mutant kdrl+ cells are largely derived from tailbud during 
somitogenesis 
    3. pax9 is expressed in the vasculature. 
    4. pax9 cell-autonomously regulates vascular patterning preferentially in 
avascular mutant embryos. 
 
Conclusions 
Chapter 3 highlights a unique mechanism for the emergence of the 
endothelial lineage in avascular mutants and further interrogates the role of pax9 
in avascular mutant endothelial patterning.  It was shown that much of the 
presumptive mesoderm in these mutants is unable to specify as kdrl+ and 
therefore contributes to another lineage that remains unscored.   
We had previously noted that much of the kdrl+ lineage in avascular 
mutants first arises in the caudal region of the tail, a location largely derived for 
tailbud mesoderm.  Using later stage lineage tracing, we showed that much of 
the endothelium in this region is derived from tailbud and that mutants displayed 
a higher percentage of tailbud mesoderm-derived endothelium.  This finding 
highlights a unique developmental source for avascular mutant endothelium and 
therefore unique mechanisms may be involved in the biology of these cells. 
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We subsequently identified pax9 as being upregulated in avascular mutant 
endothelials cells by qRT-PCR.  Originally described for its role in odontogenesis, 
pax9 has never been described as playing a role in vascular patterning.  We 
found that pax9 does, in fact, regulate proper vascular patterning to a large 
extent in mutants.  Since pax9 knockdown in wild-type embryos showed very 
little phenotype, avascular mutants allowed for the first-ever description of the 
role of this transcription factor in vascular patterning. 
Taken together, Chapter 3 represents a remarkable discovery made 
possible through the use of an attenuated model system.  We have described a 
unique developmental source for avascular mutant endothelium and a novel 
transcription factor regulating the morphogenesis of vasculature in these 
mutants.  Furthermore, the putative role for pax9 in vascular development in 
humans was highlighted by the use of HUVEC cell culture.    
 
Future Directions 
 The role of pax9 in odontogenesis has been well established [4].  pax9 
mediates mesenchymal progenitor aggregration to form tooth primordia.  Given 
that we found that the FGF inhibitor does significantly down-regulate pax9 
mRNA, it is tempting to speculate that a similar signaling pathway functions to 
aggregate mesenchymal precursors to endothelial cells.  Therefore, I propose 
the generation of a Tg(pax9:eGFP) transgenic fish for the study of FGF-
regulation of pax9 [5].  This transgenic line could be used for at least three 
purposes.  First, direct measurement of transcription output of the pax9 promoter 
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after inducible heat-shock of the Tg(hsp70l:DNFGFR) line as well as treatment 
with the FGF inhibitor, SU5402 would help strengthen the argument that FGF is 
important in avascular mutant vascular patterning.  Secondly, time-lapse 
microscopy of this transgenic in conjunction with Tg(kdrl:mCherry) at early stages 
could elucidate the source of avascular mutant kdrl+ cells: directly from tailbud 
cells or through a somitic intermediate.  Lastly, time-lapse at later stages in wild-
type and mutants, could help delineate the angiogenic mechanism(s) pax9 is 
important to, such as tip versus stalk cell phenoype.  Given that transplanted 
pax9 morphant donor cells preferentially localize to the axial vasculature, not the 
secondary vessels, at 24 hpf, I have reson to hypothesize that GFP might be up-
regulated in tip cells.    
 Furthermore, during odontogenesis, pax9 is known to interact genetically 
with another inhibitory transcription factor, msx1 [6].  In order to determine 
whether this interaction happens in endothelial cells, several experiments are 
detailed below.  First, expression levels of msx1 should be quantified in FACS-
sorted cells in comparison to other genes to establish that msx1 is in fact 
expressed in endothelial cells.  However, our microarray data did not indicate a 
change in this gene.  In situ hybridization patterns for msx1 in zebrafish have 
been published [7, 8]; its potential expression in vasculature should be more 
closely examined as well.  Intriguingly, msx1 is expressed in tailbud [7] and in 
regenerating tail-fin tissue [9], but largely missing from post-segmetation 
mesodermal tissues.  Nevertheless, knockdown of msx1 by morpholino should 
produce a similar phenotype in avascular mutants, barring any early 
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developmental function.  Humans with familial hypodontia, have been shown to 
have mutations in pax9 or msx1, indicating that both genes are not necessary 
early development [4].  Lastly, a yeast two-hybrid screen could potentially identify 
other interacting proteins and endothelial specific expression libraries are 
available.   
 
Conclusion 
 Taken together, the research contained within this thesis indicates several 
novel findings.  First, the transgenic avascular mutant model proved to be an 
effective method for the discovery of novel angiogenic genes.  Second, we have 
implicated two new genes, sox11b and pax9, in the development of the 
vasculature.  Third, we have shown that the majority of the avascular mutant 
kdrl+ cells are derived from tailbud mesoderm.  Fourth, we have shown that in the 
absence of clo or etv2 presumptive angioblasts default to an unspecified fate.  
Overall, avascular mutant kdrl+ cells have a unique transcriptional profile. 
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CHAPTER 5 
Visualizing Vascular Networks in Zebrafish: An Introduction to 
Microangiography 
 
Summary 
Visualizing the circulatory pattern in developing embryos becomes an 
essential technique for the field of cardiovascular biology.  In the zebrafish model 
system, there are currently several techniques available to visualize the circulatory 
pattern.  Microangiography is a simple technique in which a fluorescent dye is 
injected directly into the Sinus Venosus and/or the Posterior Cardinal Vein, allowing 
for the rapid labeling and easy detection of patent vessels.  Here, we compare 
microangiography to other vascular labeling techniques, describe the benefits and 
potential applications of microangiography, and give step by step instructions for 
microangiography.   
 
Introduction. 
The advent of transgenic animals has provided a unique opportunity to 
expand our current knowledge of vascular development using diverse vertebrate 
model systems.  In the majority of cases, however, the use of transgenic animals is 
not well situated for assessing the function of vasculature.  In zebrafish, multiple 
transgenic lines which express a specific fluorescent protein under an endothelial-
specific promoter have been generated [1,7-12].  However, since the majority of 
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transgenic animals express the molecular tag in all endothelial cells, it is extremely 
difficult to rely on transgenic animals to examine whether a specific vessel is used 
for circulation.  Analyzing circulating red blood cells using high power bright-field or 
video microscopes is adequate to obtain such information, but requires significant 
time and effort [13].   Microangiography can offer a simple yet sophisticated 
alternativeto visual observation under high power bright-field microscopes.   By 
labeling all patent vessels used for circulation, microangiography significantly 
reduces the time required for the observation of the circulatory pattern [1].   
Furthermore, in combination with various transgenic animals that express 
fluorescent proteins in a tissue-specific manner, one can carry out more 
sophisticated analyses of the vascular system by using microangiography. 
Application of Microangiography. 
Microangiography may be used in any scenario where the vascular 
system needs to be visualized.  For instance, microangiography can be used to 
determine the patency of developing vessels [1,14].  In addition, it can be readily 
used to assess the vascular integrity since any vascular leakage leading to 
extravasation of plasma will be labeled with injected dye [15,16].  Since 
microangiography can be used at any developmental period, this technique can be 
combined with morpholino-injected, chemical-treated, or even surgically altered 
embryos, in addition to various mutant embryos [17,18].  Once injected into the 
blood stream, dye can stay within the vasculature for a few days.  Therefore, 
microangiography can either precede or follow these treatments.  However, because 
the injected dye is passively spread within the vascular lumen, microangiography will 
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not always reveal dynamic morphology of endothelial cells such as filopodial 
extensions in the migrating tip cell.  In addition, microangiography is not an efficient 
technique to use in mutants without blood flow [19].  Even with the limitations, 
microangiography is an extremely useful technique to rapidly visualize patent 
vessels.  
Microangiography: General Considerations and Experimental Design 
When attempting an experiment using microangiography, it is useful to keep 
in mind that a number of factors will determine the experimental outcomes.  We 
have enumerated the most important factors to consider before the experimental 
design.   
1. Developmental Stage of Embryos. Dye can be injected into Sinus 
Venosus (SV) and/or Posterior Cardinal Vein (PCV) (Fig. 1).  Depending on the age 
of the embryo, the method of injection will vary slightly.  For the best results, we 
recommend trying both sites first and determine whether SV or PCV yields better 
outcomes. 
2. Condition of the Embryos. Microangiography can be combined with 
various experimental procedures as aforementioned.  However, if microangiography 
is performed in embryos that are previously treated with small chemicals or 
morpholino, any developmental delay or morphological abnormality that might 
potentially impede microangiography should be carefully examined. 
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3. Intended Method of Observation. Embryos that are injected with dye can 
be analyzed by various methods.  If the injected embryos will be analyzed after 
fixation, sufficient time must be allowed for the dye to completely perfuse the entire 
vascular system.  This can be monitored on a fluorescent microscope.  Alternatively, 
if the embryos are to be observed in vivo, attention should be paid to minimize any 
interference to the cardiac function. 
 
MATERIALS. 
1. Microinjector.  A microinjector is used to perfuse the vascular system of 
the embryos with a defined amount of dye.  Based on the mechanism used to deliver 
the dye into the embryos, there are two main types of microinjectors widely used for 
the microinjection.  Hydraulic microinjectors, such as the Nanoject (from Drummond 
Scientific) require oil to fill the injection needle.  Pneumatic microinjectors, such as 
Picospritzer (from Parker) or Femtojet (from Eppendorf) use compressed air, rather 
than oil, to push out dye into the embryos. 
2. Micromanipulator.  Although one can hold the injection needle with hand, 
using a micromanipulator to modulate the microinjector provides better control of the 
delivery of dye.  Normally, the micromanipulator can be mounted onto a stand, which 
allows the microinjector to approach the embryos at a 45° angle.  Some stand-alone 
systems (i.e., Femtojet) do not need an external micromanipulator. 
    
83 
 
3. Needle Puller.  The shape of needle is one of the most critical factors that 
affect the outcome of the microangiography.  Traditionally, the needle puller makes 
the injection needle by heating the glass capillary tube with the Tungsten fi lament 
and pulling with a defined force.  The parameters that determine the force that 
applies to the heated needle needs to be empirically determined.  The new lines of 
needle pullers, however, use a CO2 laser to heat up the glass capillary, providing 
more precise control. 
4. Injection Molds.  There are several prefabricated plastic molds available, 
which can create a series of grooves in which the embryos settle if placed on top of 
melted agarose.  These molds allow the injection to large quantity of embryos 
quickly.  Alternatively, by gluing capillary tubes or slide glass to the bottom of a Petri 
dish and pouring the agarose on top of the tubes, a homemade injection mold can 
be made.  Both work equally well and are reusable (Fig. 1). 
Solutions and Dyes. 
1. Embryo Medium: 1.0 mL Hank’s Stock #1 (8.0 g NaCl, 0.4 g KCl in 100 mL 
H2O),0.1 mL Hank’s Stock #2 (0.358 g Na2HPO4 Anhydrous, 0.60 g KH2PO4 in 100 
mL H2O), 1.0 mL Hank’s Stock #4 (0.72 g CaCl2 in 50 mL H2O), 1.0 mL Hank’s 
Stock #5 (1.23 g MgSO4 × 7H2O in 50 mL H2O), 1.0 mL fresh Hank’s Stock #6 (0.35 
g NaHCO3 in 10 mL H2O), and 95.9 mL double distilled water.  Alternatively, use 1.5 
mL stock salts (i.e., Instant Ocean) added to 1 L distilled water to achieve 60 μg/mL 
final concentration. 
2. HEPES: 10 mM HEPES, pH 7.6 is added to the injection mix (5 mM final 
concentration).  HEPES will buffer the injection mix to physiological pH. 
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3. Dye: Dextran-conjugated fluorophores are easy to use and effective. 
Alternatively, fluorescent microspheres such as Quantum dot can be used.  Based 
on the fluorophores, these dyes have a wide range of excitation and emission 
spectra, allowing the user more flexibility. 
Method. 
 1. Use a pair of forceps to remove the chorion.  Alternatively, a short pulse of 
Pronase treatment can be used to dechorionate large numbers of embryos [20].  
Removal of the chorion will allow for more efficient penetration of the injection 
needle into embryos. 
2. Prepare the injection mold by adding 3% methylcellulose onto the petri 
dish. Methylcellulose immobilizes the embryos within the well and allows for easy 
repositioning, while the well itself acts as a backstop (Fig. 1). 
3. Place embryos into wells using a glass Pasteur pipette.  Avoid adding 
excessive embryo medium while transferring the embryos since this will dilute the 
Tricaine. 
4. Add a layer of 40 μL/mL Tricaine in embryo media on top of the 3% 
methylcellulose.  The most critical aspect of zebrafish cardinal vein dye injection is 
the concentration of Tricaine.  Soaking the embryos in a solution of 40 μL/mL 
Tricaine in embryo medium will allow for the immobilization of the embryo without 
immediately stopping the heart. 
5. Prepare the microinjector.  A standard microcapillary tube pulled and cut to 
5–10 nm is sufficient for this method.  Additional grinding or sharpening of the 
needles is not necessary.  The injection needle should be filled with dye mix.  Turn 
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and dial the micromanipulator such that the needle is close to the first embryo (Fig. 
2). 
6. For 24–72 hpf embryos, inject the dye to the PCV plexus.  For older 
embryos, one can inject directly into the SV, through the pericardium.  We normally 
inject 4.6 nL of dye mixture into 24 hpf embryos.  Injecting both areas on the same 
embryo will ensure rapid perfusion of the dye (see Note 1).  By gently moving the 
needle in a circular motion, one can “drill” through external tissues that may be 
difficult to penetrate (see Note 2).  If embryos will not be immediately imaged, after 
injecting ~20 embryos, draw them up using a glass Pasteur pipette and put them into 
fresh media.  If the heart stops, dye will typically take longer to disseminate, thus, 
washing out the anesthetic with embryo media can speed perfusion.  Zebrafish 
embryos are typically reared at 28.5°C, but we find that recovery and imaging work 
well, if not better, at room temperature.  
7. For imaging the result of microangiography, wait at least 10 min for 
perfusion to complete.  We often inject on a brightfield microscope (see Note 3), but 
injections may be performed on a fluorescence microscope to determine 
immediately if the dye has been perfused (see Notes 4 and 5). 
8. Alternatively, embryos can be fixed for later observation since Dextran-
conjugated probes can be fixed.  After injection and perfusion, embryos are washed 
once with PBS and put into 1 mL of 4% PFA in PBS and incubated overnight at 4°C.  
Once fixed, embryos can be stored in methanol at for −20°C for several weeks.  
Either sectioned or whole embryos can be analyzed by confocal microscopy after 
fixation (see Note 6) (Fig. 3). 
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9. Concluding Remarks. 
Microangiography is a relatively simple, yet powerful technique to visualize 
patent vessels.  It also provides a powerful way to analyze vascular development 
and maintenance in combination with the increasing number of available transgenic 
lines.  For instance, using endothelial specific transgenic lines, one can easily 
distinguish lumenized vessels within the developing vascular network.  Furthermore, 
in combination with transgenic lines that label adjacent tissue, one can analyze the 
functional relationship between the vascular network and neighboring tissues.  In 
addition, microangiography can be extremely useful to detect the subtle changes of 
the circulatory pattern since it can rapidly visualize the patent vessels.  By selectively 
labeling those vessels used for circulation, microangiography can provide 
information on the functionality of specific vessels, which cannot be achieved by 
analyzing endothelial specific transgenic lines.  With the advent of chemical biology 
and powerful imaging techniques, the potential application of microangiography is 
ever increasing. 
Notes. 
 1. Embryos may be injected at multiple sites to ensure rapid perfusion of dye. 
2. Embryos may also be injected in the Common Cardinal Vein which is 
located below the Sinus Venosus before 4 days post-fertilization. 
3. Dextran-conjugated dyes, particularly Rhodamine, can be detected using 
the bright-field scope.  Therefore, it is possible to monitor the perfusion effi cacy 
immediately after the dye injection. 
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4. We have observed that embryos may survive a significant and acute 
puncture wound.  Take the time to empirically determine how much trauma the 
embryos can withstand.  
5. Similarly, determine the proper needle diameter: thinner takes less force to 
penetrate tissues but may flex too much with mature tissues while thicker needles 
create more trauma.  
6. Any unused Dextran-conjugated dye may be frozen at −20°C and reused  
for longer than 6 months. 
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FIGURES: 
 
 
 
 
 
 
 
Figure 5.1:  Schematic drawings of microangiography.  
(a) An anesthetized embryo will be lined up against slide glass within the petri 
dish.  (b) Dye can be injected into either the sinus venosus (I) or the posterior 
cardinal vein (PCV) of the embryo. 
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Figure 5.2:  Commonly used microinjectors for microangiography.  
Both hydraulic and pneumatic microinjectors can be used to deliver dye into 
the embryos to visualize vascular network.  An example of a hydraulic microinjector 
(a) and a pneumatic microinjector (b) are shown. 
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Fig. 5.3. An exemplary result of microangiography.   
 
The trunk region of a 60 hpf embryo after the microangiography.  (a) All the 
vascular network is visualized by Tg(kdrl:EGFP), which expresses EGFP under an 
endothelial specific promoter, kdrl.  (b) Microangiography of the same embryo.  (c) 
Merged image.  Notice microangiography is only visualizing vessels actively used for 
circulation.  For instance, the dorsal vein (white arrowhead) which constricts and 
shrinks to become the hematopoietic niche, or the dorsal longitudinal anastomotic 
vessel (yellow asterisk) which is not patent yet are not labeled with 
microangiography. 
 
    
91 
 
REFERENCES 
1.  S. Isogai, M. Horiguchi and B. M. Weinstein: The vascular anatomy of the 
developing zebrafish: an atlas of embryonic and early larval 
development, Dev Biol 2001, 230:278–301. 
 
2.  N. D. Lawson and B. M. Weinstein: Arteries and veins: making a difference 
with zebrafish, Nat Rev Genet 2002, 3:674–682. 
 
3.  R. K. Lee, D. Y. Stainier, B. M. Weinstein and M. C. Fishman: 
Cardiovascular development in the zebrafish Endocardial progenitors 
are sequestered within the heartfield, Development 1994, 120:3361–3366. 
 
4.  D. Y. Stainier, B. Fouquet, J. N. Chen, K. S. Warren, B. M. Weinstein, S. E. 
Meiler, M. A. Mohideen, S. C. Neuhauss, L. Solnica-Krezel, A. F. Schier, F. 
Zwartkruis, D. L. Stemple, J. Malicki, W. Driever, and M. C. Fishman: 
Mutations affecting themformation and function of the cardiovascular 
system in the zebrafish embryo, Development 1996, 123:285–292. 
 
5.  M. R. Swift and B. M. Weinstein: Arterial-venous specifi cation during 
development, Circ Res 2009, 104:576–588. 
 
6.  D. Y. Stainier, R. K. Lee and M. C. Fishman:Cardiovascular development in 
the zebrafish Myocardial fate map and heart tube formation, 
Development 1993, 119:31–40. 
 
7.  N. C. Chi, R. M. Shaw, B. Jungblut, J. Huisken, T. Ferrer, R. Arnaout, I. Scott, 
D. Beis, T. Xiao, H. Baier, L. Y. Jan, M. Tristani-Firouzi and D. Y. Stainier: 
Genetic and physiologic dissection of the vertebrate cardiac conduction 
system, PLoS Biol 2008, 6:e109. 
 
8.  J. Choi, L. Dong, J. Ahn, D. Dao, M. Hammerschmidt and J. N. Chen: FoxH1 
negatively modulates flk1 gene expressionand vascular formation in 
zebrafish, Dev Biol 2007, 304:735–744. 
 
9.  S. W. Jin, D. Beis, T. Mitchell, J. N. Chen and D. Y. Stainier: Cellular and 
molecular analyses of vascular tube and lumen formation 
in zebrafish, Development 2005, 132:5199–5209. 
 
10.  N. D. Lawson and B. M. Weinstein: In vivo imaging of embryonic vascular 
development using transgenic zebrafi sh, Dev Biol 2002, 248:307–318. 
 
11.  T. Motoike, S. Loughna, E. Perens, B. L. Roman, W. Liao, T. C. Chau, C. D. 
Richardson, T. Kawate, J. Kuno, B. M. Weinstein, D. Y. Stainier and T. N. 
    
92 
 
Sato: Universal GFP reporter for the study of vascular development, 
Genesis 2000, 28:75–81. 
 
12.  B. L. Roman, V. N. Pham, N. D. Lawson, M. Kulik, S. Childs, A. C. Lekven, D. 
M. Garrity, R. T. Moon, M. C. Fishman, R. J. Lechleider, and B. M. Weinstein: 
Disruption of acvrl1 increases endothelial cell number in zebrafish 
cranial vessels, Development 2002, 129:3009–3019. 
 
13.  T. Schwerte, D. Uberbacher and B. Pelster: Non-invasive imaging of blood 
cell concentration and blood distribution in zebrafish Danio rerio 
incubated in hypoxic conditions in vivo, J Exp Biol 2003, 206:1299–1307. 
 
14.  M. Kamei, W. B. Saunders, K. J. Bayless, L. Dye, G. E. Davis and B. M. 
Weinstein: Endothelial tubes assemble from intracellular 
vacuoles in vivo, Nature 2006, 442:453–456. 
 
15.  D. A. Buchner, F. Su, J. S. Yamaoka, M. Kamei, J. A. Shavit, L. K. Barthel,  B. 
McGee, J. D. Amigo, S. Kim, A. W. Hanosh, P. Jagadeeswaran, D. Goldman, 
N. D. Lawson, P. A. Raymond, B. M. Weinstein, D. Ginsburg and S. E. Lyons: 
pak2a mutations cause cerebral hemorrhage in redhead zebrafish, Proc 
Natl Acad Sci U S A 2007, 104:13996–14001. 
 
16.  J. Liu, S. D. Fraser, P. W. Faloon, E. L. Rollins, J. Vom Berg, O. Starovic-
Subota, A. L. Laliberte, J. N. Chen, F. C. Serluca and S. J. Childs: A betaPix 
Pak2a signaling pathway regulates cerebral vascular stability in 
zebrafish, Proc Natl Acad Sci U S A 2007, 104:13990–13995. 
 
17. B. M. Hogan, F. L. Bos, J. Bussmann, M. Witte, N. C. Chi, H. J. Duckers, and 
S. Schulte-Merker: Ccbe1 is required for embryonic lymphangiogenesis 
and venous sprouting, Nat Genet 2009, 41:396–398. 
 
18.  S. Nicoli, C. Standley, P. Walker, A. Hurlstone, K. E. Fogarty and N. D. 
Lawson: MicroRNA-mediated integration of haemodynamics and Vegf 
signalling during angiogenesis, Nature 2010, 464:1196–1200. 
 
19.  T. P. Zhong, M. Rosenberg, M. A. Mohideen, B. Weinstein and M. C. 
Fishman: gridlock, an HLH gene required for assembly of the aorta in 
zebrafish, Science 2000, 287:1820–1824. 
 
20.  M. Westerfield: The zebrafish book, A Guide for the laboratory use of 
zebrafish (Danio rerio), (2000) 4th Ed. University of Oregon. 
 
CHAPTER 6 
LRP1-Dependent Endocytic Mechanism Governs the Signaling Output of the Bmp 
System in Endothelial Cells and in Angiogenesis 
 
Summary 
Previous studies have identified the Bmp signaling pathway as a major modulator 
of venous angiogenesis.  There is a multitude of well-characterized activators, inhibitors, 
and modulators of the BMP signaling pathway.  One such molecule is Bmper, which, 
depending on context, can act as both an inhibitor and an activator.  Using biochemical 
methods it was shown that Bmper functionally interacts with the LDL receptor-related 
protein 1, LRP1.  Here we have shown that LRP1 gene function is necessary for proper 
vascular development, particularly those processes that are mediated by Bmp signaling.  
Using zebrafish transplantation, I showed that knockdown of LRP1 in donor cells 
excluded them from the venous vascular front during cardinal vein plexus development.  
 
Introduction 
Bone morphogenetic proteins (Bmps) are essential for embryonic vascular 
development, as illustrated by many severe, inherited vascular diseases associated with 
disrupted Bmp signaling [1].  One facet of regulation of Bmp signaling is provided by 
extracellular molecules that “fine-tune” Bmp signaling by modulating (usually inhibiting) 
Bmp’s interaction with surface receptors and subsequent downstream signaling events 
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[2].  Of these extracellular modulators of Bmp signaling, Bmper (Bmp-binding 
endothelial cell precursor derived regulator, the vertebrate ortholog for crossveinless-2 
in Drosophila) is a critical determinant of endothelial functions such as differentiation, 
migration, and angiogenesis [3–6].  Bmper can both promote and inhibit Bmp activity 
[6,7], confounding the development of a working model to explain how Bmper impacts 
Bmp signaling.  However, we recently found that Bmper modulates Bmp4 activity via a 
concentration dependent, endocytic trap-and–sink mechanism, with low levels of Bmper 
promoting and high levels inhibiting Bmp4 signaling, thereby accounting for the biphasic 
nature of Bmper’s regulation of Bmp4 activity [7].  Our previous data suggested that 
endocytosis of the Bmper/Bmp4 complex may be critical in determining the inhibitory 
effect of Bmper on Bmp4 function.  However, gaps remained in understanding 
how activation and inhibition of Bmp4 signaling by Bmper were coupled and the 
mechanism by which the Bmper/Bmp4 complex was endocytosed.   
Here we report that LRP1 (LDL receptor-related protein 1) is a novel endocytic 
receptor for Bmper and a coreceptor of Bmp4 that is essential for mediating Bmp4 
signaling.  A requisite role for LRP1 in zebrafish angiogenesis is observed in that 
knockdown of lrp1 decreases Smad1/5/8 activity and abnormal cardiovascular 
development.  Together, these data demonstrate that LRP1 regulates Bmp4-mediated 
endothelial function and vascular development in vivo and is therefore a bone fide 
component of the Bmp signaling pathway. 
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Methods 
Generation of Cell Lines 
For stable mouse endothelial cell (MEC) cell line construction, MECs were 
transduced with LRP1 or control shRNA lentiviral particles, and positive colonies were 
screened with puromycin and evaluated by Western blot analysis.  
Chemical Cross-Linking in Intact Cells, Immunoblotting, Immunoprecipitation, 
and Ligand Blotting 
Bmper-treated MECs were crosslinked with dithiobis(succinimidylproprionate) for 
immunoprecipitation and matrix-assisted laser desorption/ionization-time of flight 
analysis.  Immunoblotting, immunoprecipitation, and ligand blotting were performed 
following our previous protocols [7, 8]. 
Fluorescence Energy Transfer Experiments 
Experiments were performed following a previously published protocol [9].  
Donor, acceptor, and fluorescence energy transfer images were acquired sequentially 
using fixed excitation and emission filters, and image processing was performed.  
In Vitro Matrigel Tubulogenesis Assay 
Endothelial cell tube formation was analyzed with the Matrigelbased tube 
formation assay [10].  
Morpholino Injections and Zebrafish Analysis 
Morpholino oligonucleotides (MOs) were produced by Gene Tools (Philomath, 
OR).  All MOs were injected into 1 to 4 cell stage embryos as previously described. 11 
Zebrafish (Danio rerio) vascular development was analyzed following previously 
published methods [12].  Please see the expanded Methods section, available in the 
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online-only Data Supplement for details regarding reagents, cell culture, 
immunoblotting, ligand blotting, immunofluorescence, and statistical analysis.  
Transplantation Assay 
Tg(kdrl:eGFP)S843 embryos were injected with either control or LRP1 
morpholino/tracking dye mix at the one cell stage and allowed to develop to between 
sphere and germ ring stage.  Donors and recipients were manually dechorionated at the 
16 cell stage and allowed to develop in 30% Danieau solution at 28.5°C.  
Transplantations were performed under 40 to 60X magnification using a Hamilton 
syringe with a micrometer drive and micromanipulator in a standard petri dish containing 
a bed of 3% agarose in 30% Danieau with 150 individual embryo wells (Mold available 
from Adaptive Science Tools) at room temperature  Donor cells were targeted to the 
presumptive mesendoderm at the ventral margin.  Embryos were allowed to recover for 
one hour post-transplantation at room temperature and then washed three times with 
10% Danieau solution and placed at 28.5’C.  Representative images were taken using 
the whole mount immunohistochemistry.  Briefly, chick anti-GFP primary antibody from 
Abcam and donkey anti-chick-488 secondary from Jackson Immunoresearch were used 
to boost GFP signal after storing embryos in methanol.  
 
Results 
LRP1 Associates With Bmper in MECs 
Previously we demonstrated that endocytosis of the Bmper/Bmp4 complex is 
critical for Bmper-mediated Bmp4 signaling [7].  However, the mechanism governing 
this endocytosis remained unclear.  Hypothesizing that Bmper may interact with a 
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partner to achieve endocytosis, we used matrix-assisted laser desorption/ionization-time 
of flight mass spectrometry as an inductive unbiased method of identifying Bmper-
associated proteins in MECs.  LRP1, a well-defined endocytic receptor, associated with 
Bmper in MECs (Figure 6.1A; Online Figure 6.7A).  Confocal imaging of Bmper-treated 
MECs revealed that Bmper and LRP1 colocalize on the plasma membrane and in 
intracellular vesicles (Figure 6.1B).  Immunoprecipitating for LRP1 and immunoblotting 
for Bmper (or the reverse, or Bmper ELISA) demonstrated that full-length Bmper 
associates with LRP1 in MEC lysates (Figure 6.1C, 6.7B and 6.7C), confirming our 
matrix-assisted laser desorption/ionization-time of flight and immunofluorescence data.  
Notably, this association was not affected by the addition of Bmps (Figure 6.7D and 
6.7E).  Because Bmp4 may bind Bmper through its amino-terminal domain [7,13], its 
inability to disrupt the LRP1/Bmper association suggested that LRP1 may bind a 
different domain of Bmper and carboxyl-terminal domain (CTD) fragments of Bmper 
associated with LRP1 (Figure 6.1C, 6.7D), indicating that Bmper may form a ternary 
complex with LRP1 and Bmp4 through respective associations with its CTD and amino-
terminal domain.  Consistent with this hypothesis, lysates of Bmp4-treated MECs 
immunoprecipitated with an anti-LRP1 antibody revealed the presence of LRP1/Bmp4 
heterocomplexes (Online Figure 6.7F). 
Like other members of the LDL receptor family, LRP1 is a heterodimer composed 
of a 515-kDa α chain possessing 4 extracellular ligand binding domains (LBDs) and an 
85-kDa membrane-anchored β chain [14].  Ligand blotting analysis with full-length LRP1 
revealed that Bmper associates with both the α and β chains of LRP1 (Figure 6.1D).  To 
determine which LBD of LRP1 is required for binding to Bmper, cells were transfected 
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with membrane-containing mini-LRP1 receptors (mLRP1-415; Figure 6.1E, left panel) 
and analyzed via ligand blotting.  LBDIII/IV exhibited the strongest association with 
Bmper, whereas LBDII had only a weak association and LBDI did not associate with 
Bmper at all (Figure 6.1E, right top panel), consistent with what is found with other 
LRP1 ligands such as RAP1 [15].  However, Bmper also binds to the β chain of LRP1, 
making Bmper unique among other known LRP1 ligands.  The significance of Bmper 
binding to LRP1's β chain remains unknown; however, internalized CTD fragments of 
Bmper may bind LRP1 and modulate its association with scaffold proteins that 
participate in LRP1-dependent signaling mechanisms [16].  Together, these data 
identify that LRP1, a recognized endocytic receptor, associates with Bmper in MECs 
and therefore could be responsible for endocytosis of Bmper/Bmp4 complexes.  
LRP1 Is Required for Physiological Bmper Internalization 
Previously, we found that Bmper undergoes endocytosis via an unknown 
mechanism that modulates downstream Bmp4 signaling [7].  Given our observation of a 
direct interaction between Bmper and the endocytic receptor-LRP1, we hypothesized 
that LRP1 may act as an endocytic receptor for Bmper and examined cell lysates from 
LRP1-knockdown (or control) MECs treated with Bmper.  The level of internalized 
Bmper in control MECs increased over time, peaking at 60 minutes and subsequently 
decreased, probably due to degradative processing, as previously demonstrated7 
(Figure 6.2A and 6.2B).  LRP1-knockdown MECs also demonstrated a time-dependent 
increase in Bmper internalization; however, internalization was substantially less than in 
control MECs (Figure 6.2B).  When cells were treated with increasing doses of Bmper, 
the presence of cytoplasmic Bmper in control MECs increased, an effect that was 
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significantly decreased in LRP1-knockdown cells (Figure 6.2C and 6.2D).  Similar 
results were observed in mouse embryonic fibroblasts (Figure 6.8A– 6.8D).  These data 
suggest that the majority, but not all, of Bmper is via an LRP1-dependent mechanism 
and we further explored the role that LRP1 plays in Bmper/Bmp4 endocytosis.  
We used confocal microscopy to investigate whether LRP1 is involved in the 
previously reported internalization and transport of Bmper to endosomes [7].  Following 
Bmper internalization, both LRP1 and Bmper were detected in a subset of vesicles 
expressing EEA-1 and Rab-7 (endosome markers; Figure 6.8E and 6.8F).  LRP1-
knockdown MECs contained far fewer Bmper-containing EEA-1 and Rab-7 positive 
endosomal vesicles compared to control MECs (Figure 6.2E).  Similar results were 
found in LRP1 null mouse embryonic fibroblasts (Figure 6.8G).  Further subcellular 
fractionation experiments confirmed this localization (Figure 6.8H).  These data 
collectively indicate that LRP1 influences the endosomal localization of Bmper and acts 
as an endocytic receptor for Bmper.  We have previously shown that Bmper is 
internalized in a complex together with Bmp4 and Bmp receptors and that endocytosis 
of this holocomplex is critical for modulating Bmp4 signaling [7].  Therefore, we next 
investigated whether the interaction between LRP1 and Bmp receptors could influence 
Bmp4-dependent Smad1/5/8 signaling in endothelial cells. 
 
LRP1 Is Associated With Bmp Receptor Type IB/Activin-Like Kinase Receptor 6 
LRP1 functions as a coreceptor for ligands such as transforming growth factor-β 
and NMDA [17,18].  Given our data demonstrating that LRP1 is an endocytic receptor 
for Bmper, we hypothesized that LRP1 may act as a coreceptor of Bmp receptors.  
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There are multiple Bmps (Bmp2, 4, and 6) and Bmp type I receptors (activin-like kinase 
receptor [ALK]1, 2, 3, and 6) in MECs and specific siRNA knockdown of ALK2, 3, and 6 
(but not ALK1) inhibited Bmp4-induced Smad1/5/8 phosphorylation (Figure 6.8IA–IIIC).  
Given that our previous data identified ALK6 as a Bmp4 type I receptor that mediates 
Bmp-dependent endothelial migration and angiogenesis [10], we used ALK6 as a 
representative Bmp type I receptor in the following experiments.  Fluorescence energy 
transfer imaging analysis demonstrated the close proximity of cyan fluorescent protein-
tagged ALK6 (Figure 6.3A) and yellow fluorescent protein-tagged mLRP2 in cytoplasmic 
vesicles and plasma membranes of transfected cells (Figure 6.3B), indicating that LRP1 
and ALK6 could physically interact in cells.  Coimmunoprecipitation of lysates from cells 
transfected with a wild-type ALK6 plasmid (ALK6-WT; Figure 6.3A) and each mLRP 
construct (Figure 6.1E) confirmed this association (Figure 6.3C).  Additionally, when 
cells were transfected with a LRP1β construct (Figure 6.3A), the LRP1 and ALK6 
association persisted (Figure 6.3D), indicating that this association likely occurs through 
the LRP1β chain.  Because Bmper could bind to this region of LRP1 (Figure 6.1D), this 
interesting observation suggests that both Bmper and Bmps influence LRP1 signaling, 
thereby initiating cross-talk between the LRP1 and Bmp signaling pathways.  
To determine the domains of ALK6 involved in the interaction with LRP1, ALK6 
deletion mutants were constructed (Figure 6.3A).  Both ALK6-CTD and ALK6-protein 
kinase domain coimmunoprecipitated with mLRP2, indicating that the cytoplasmic 
region of ALK6 is required for the association of ALK6 with mLRP2 (Figure 6.3E).  
However, the association of mLRP2 with ALK6-CTD and protein kinase domain was 
decreased in comparison to mLRP2 binding to ALK6-WT, suggesting that CTD of ALK6 
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is required but not sufficient for the association with mLRP2.  Similar results were 
observed with the interaction of ALK6 and mLRP4 (Figure 6.8ID).  Collectively, we 
conclude that the intracellular domains and possible membrane region of ALK6 are 
required for the association with LRP1.  Because the protein kinase domain of ALK6 is 
critical for downstream Bmp-mediated Smad1/5/8 phosphorylation [19], next we tested 
whether the ALK6 and LRP1 interaction was involved in Bmp4-regulated Smad1/5/8 
signaling induced by Bmper. 
Endocytosis of the Bmper/Bmp4 Complex Is Required for Both Stimulatory and 
Inhibitory Regulation of Bmp4 Signaling by Bmper 
We previously demonstrated that endocytosis of the Bmper/Bmp4 complex is 
required for the inhibitory effect of Bmper on Bmp4 signaling [7], but whether 
endocytosis of the Bmper/Bmp4 complex is also required more generally for Bmper-
dependent Bmp4 signaling regulation remained unclear.  Therefore, we used 3 
endocytosis inhibitors—chlorpromazine, chloroquine (CQ), and bafilomycin A1—in 
MECs and evaluated the subsequent effect on Bmp4-dependent phosphorylation of 
Smad1/5/8.  Treatment of MECs with Bmp4 alone or in the presence of 
substoichiometric concentrations of Bmper increased Smad1/5/8 phosphorylation 
(Figure 6.4A, lanes 2, 4, 12, and 14; Figure 6.10A), consistent with our previous 
observations that substoichiometric ratios of Bmper to Bmp4 enhances Bmper-
dependent Bmp4 signaling [7].  However, when cells were pretreated with 
chlorpromazine to prevent clathrin-mediated endocytosis, the level of Smad1/5/8 
phosphorylation induced by either Bmp4 alone or Bmp4 plus Bmper in 
substoichiometric concentrations was substantially decreased (Figure 6.4A, lanes 7 and 
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9; Figure 6.10B), indicating that Bmper-mediated enhancement of Bmp4 signaling 
requires endocytosis of the Bmper/Bmp4 complex.  Next we investigated whether Rab4-
mediated rapid recycling is required for Bmper's promoting effect on Smad1/5/8 
phosphorylation.  Rab4 siRNA knockdown resulted in a significant decrease in 
Smad1/5/8 phosphorylation induced by Bmp4 alone or Bmp4 plus Bmper in 
substoichiometric concentrations (Figure 6.4B, Figure 6.10C).  This suggests that the 
Rab4-mediated rapid recycling route is required for both Bmp4 activity and the 
promoting effect of Bmper at stoichiometric concentrations.  This observation, combined 
with our previous data demonstrating that endocytosis is also necessary for the 
inhibition of Bmp4 signaling caused by suprastoichiometric concentrations of Bmper in 
the Bmper/Bmp4 complex [7], indicates that endocytosis is required for all aspects of 
Bmper-mediated regulation of Bmp4 signaling. 
We next examined the effect that CQ and bafilomycin A1 had on Bmper-
mediated Bmp4 signaling.  Treatment of cells with CQ did not affect the ability of Bmp4 
alone or Bmp4 plus Bmper in substoichiometric concentrations to induce Bmp4-
mediated Smad1/5/8 phosphorylation (Figure 6.4A, lanes 17 and 19; Figure 6.10D).  
However, CQ treatment relieved the inhibitory effect of Bmp4 in the presence of 
suprastoichiometric concentrations of Bmper, resulting in augmented Smad1/5/8 
phosphorylation (Figure 6.4A, compare lanes 15 and 20).  A similar effect on Smad1/5/8 
phosphorylation was obtained with bafilomycin A1 pretreatment (Figure 6.10E).  
Because CQ and bafilomycin A1 prevent endosomal acidification and inhibit endosome 
fusion and lysosomal degradation, our data suggest that the inhibition of Bmp signaling 
by suprastoichiometric concentrations of Bmper involves the lysosomal degradation of 
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the Bmper/Bmp4/Bmp receptor (BMPR) complex, and not simply endocytosis of the 
signaling complex as previously thought [7].  Collectively, these data demonstrate that 
endocytosis is a crucial process linked to Bmper's ability to both activate and inhibit 
Bmp4 signaling.  In addition, the inhibitory effect of suprastoichiometric concentrations 
of Bmper on Bmp4 signaling may involve the lysosomal degradation of the Bmper/Bmp4 
signaling complex. 
LRP1 Is Required for Bmper/Bmp4-Dependent Signaling 
We next examined the role that LRP1 plays in Bmper-dependent Bmp4 signaling.  
Following treatment with Bmp4 and Bmper, Smad1/5/8 phosphorylation was evaluated 
in LRP1-knockdown MECs.  Not surprisingly, LRP1-knockdown inhibited Bmper and 
Bmp4 internalization in these cells (Figure 6.4C) and decreased Smad1/5/8 
phosphorylation induced by Bmp4 alone and by Bmp4 plus Bmper in substoichiometric 
concentrations (Figure 6.4C, lanes 7, 9; Figure 6.10F), supporting that endocytosis is 
required for Bmper-dependent enhancement of Bmp4 signaling.  Interestingly, LRP1-
knockdown in MECs relieved the inhibitory effect of suprastoichiometric concentrations 
of Bmper on Bmp4-dependent Smad1/5/8 phosphorylation (Figure 6.4C, lane 10), 
proving that LRP1 mediates the inhibitory effect of suprastoichiometric concentrations of 
Bmper on Bmp4 signaling.  These data demonstrate the pivotal role that LRP1 plays in 
Bmper-mediated Bmp4 signaling and support the theory that endocytosis of the 
Bmper/Bmp4 complex is essential for both the stimulatory and inhibitory actions that 
Bmper exerts on Bmp4 signaling.  
To activate Bmp signaling, BMPRI/II heterodimers must form before Smad1/5/8 
phosphorylation occurs [20].  Having established that LRP1 is required for Bmper-
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dependent regulation of Bmp4 signaling, we tested the involvement of LRP1 in the 
regulation of ALK6/BMPRII heterodimerization.  ALK6/BMPRII heterodimers were 
detected in control MECs under basal conditions (Figure 6.4D, lane 1) with the level 
increasing steadily with the addition of Bmp4, or Bmp4 plus substoichiometric 
concentrations of Bmper (Figure 6.4D, lanes 2 and 4; Figure 6.10G).  In contrast, when 
cells were treated with Bmper alone or suprastoichiometric ratios of Bmper to Bmp4, the 
level of ALK6/BMPRII heterodimerization was similar to that seen under basal 
conditions (Figure 6.4D, lane 5).  Surprisingly, in LRP1-knockdown MECs, the decrease 
of LRP1 protein level resulted in a greater abundance of ALK6/BMPRII heterodimers in 
the basal state (Figure 6.4D, comparing lane 6 to lane 1), suggesting that LRP1 
competes with BMPRII for association with ALK6.  In contrast, when LRP1-knockdown 
MECs were treated with Bmp4, Bmper, or Bmp4 and both low and high concentrations 
of Bmper, ALK6/BMPRII heterodimers were decreased in abundance (Figure 6.4D, 
lanes 7–10, compared to lane 6).  These data suggest that LRP1 regulates the 
interaction of ALK6 with BMPRII under both basal and stimulated conditions—blocking 
the association of the receptors in the absence of Bmp4 or Bmper and promoting 
receptor interaction once stimulation with Bmp4 and/or Bmper at substoichiometric 
concentrations occurs.  Other Bmp type II receptors (eg, activin receptor type II) showed 
different behavior in response to LRP1 (Figure 6.10H).  In addition, the binding of ALK6 
and BMPRII was similar but not the same in mouse embryonic fibroblasts (Figure 6.10I).  
Because exogenous mLRPs and ALK6 were associated in HEK293 cells (Figure 6.3), 
we wanted to know whether they form a complex in MECs and, if so, how Bmper/Bmp4 
affect this association.  Immunoprecipitation assays using MEC lysates confirmed that 
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ALK6 and LRP1 were associated in MECs.  Whereas their interaction was inhibited by 
Bmp4, it was increased by treatment with Bmper alone, or Bmp4 and Bmper at both 
sub- and suprastoichiometric concentrations (Figure 6.4E, Figure 6.10J), suggesting 
that the LRP1 and ALK6 association is dynamically regulated by Bmp4 and Bmper, 
which may explain the differential effects of Bmper at sub- or suprastoichiometric 
concentrations on Smad1/5/8 activation.  
LRP1 Regulates Bmper/Bmp4-Dependent Endothelial Migration and Angiogenesis 
Our data demonstrating that LRP1 is required for the Bmper-mediated Bmp4 
signaling module suggests that LRP1 could influence physiological outcomes of Bmper-
mediated Bmp4 signaling such as endothelial migration and angiogenesis.  In Boyden 
chamber migration assays, both Bmp4 and Bmper enhanced endothelial migration in 
MECs whereas a Bmp4 neutralizing antibody blocked Bmp4-induced cell migration 
(Figure 6.10K and IVL), consistent with previous reports [3,21].  However, LRP1 
knockdown in MECs completely inhibited migration induced by Bmp4, Bmper alone, or 
Bmp4 plus a substoichiometric concentration of Bmper.  Furthermore, LRP1 knockdown 
in MECs relieved the inhibition on cell migration caused by the combined treatment of 
Bmp4 plus suprastoichiometric concentrations of Bmper, consistent with our finding that 
the inhibition of Smad1/5/8 phosphorylation induced by high concentrations of Bmper 
was also relieved in the absence of LRP1 (Figure 6.4C).  To study the role of LRP1 in 
angiogenesis, we performed an in vitro Matrigel tubulogenesis assay.  Similar to the 
effects on endothelial migration, LRP1 knockdown in MECs blocked tube formation 
induced by Bmp4, Bmper, or the cotreatment of Bmp4 plus Bmper at the 
substoichiometric concentrations (Figure 6.4F).  However, LRP1-knockdown MECs 
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demonstrated increased tube formation on the treatment of Bmp4 and Bmper at 
suprastoichiometric concentrations (Figure 6.4F).  These data establish that the 
biochemical model we constructed through in vitro analysis holds true in a 
physiologically relevant cellular setting, demonstrating that LRP1 is a critical 
determinant of Bmper-mediated Bmp4 signaling events. 
LRP1 Is Necessary for Cardiovascular Development in Zebrafish 
The fact that Bmper/Bmp signaling pathways are essential for vascular 
development in zebrafish [5,12], along with our observations of a clear reliance of 
Bmper-mediated Bmp4 signaling on LRP1, prompted us to test whether LRP1 may also 
play an important role in Bmp4-dependent cardiovascular development. The 
spatiotemporal expression of lrp1 during zebrafish embryonic development was 
examined. Weak lrp1a expression was observed at 12 hours post fertilization (hpf), 
whereas a stronger, symmetrical expression signal could be detected at the lateral 
dorsal aorta at 24 hpf and other vascular structures at later time points (Figure 6.5A, 
Figure 6.11A).  Interestingly, the expression pattern of lrp1a closely paralleled that 
of bmper [5], in that lrp1a was expressed in structures that have Bmp and vasculogenic 
activity, such as lateral dorsal aorta and dorsal longitudinal anastomotic vessel.  
To determine the importance of lrp1a in vasculogenesis, we used lrp1a-specific 
MOs to knock down lrp1a during zebrafish embryonic development.  lrp1a knockdown 
efficiently decreased embryonic levels of lrp1a RNA as determined by RT-PCR (Figure 
6.11B) and resulted in an abnormal vascular phenotype, illustrated by delayed dorsal 
and intersegmental vessel formation, fewer vascular branches within the caudal vein 
plexus, and a large swollen vascular lumen with ectopically-placed Kdr+ cells (Figure 
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6.5B), which have also been described for bmper morphants  [5].  
Additionally, lrp1a morphants demonstrated disrupted blood flow and a slower or 
stopped heart beat (dsRed images in Figure 6.11C).  Increased doses of lrp1a MOs 
resulted in a higher percentage of affected embryos (increasing from 75%–100%) at 24 
hpf.  This dose-dependent effect of the lrp1a MO was specific to the knockdown 
of lrp1a RNA and not due to activation of the p53-dependent cell death pathway 
[22] (Figure 6.11C–VF, Movies I–III).  Knockdown of the second lrp1 gene (lrp1b, 
ENSDART00000088208, chr. 23), either alone or with lrp1a resulted in a similar 
vascular phenotype, suggesting that the lrp1 genes possess redundant functions 
(Figure 6.11G). 
Next, we investigated whether the vascular defect of lrp1 morphant fish is cell-
autonomous by performing cell transplantation assays.  Control or lrp1 MO-injected 
donor cells were transplanted into wild-type recipient embryos.  We observed that both 
control and lrp1 MO-injected cells contributed to blood, endothelial structures (dorsal 
aorta, cardinal vein, caudal vein plexus, and intersegmental vessel) and other structures 
(somite, notochord, etc.) similarly (data not shown), suggesting that lrp1 MO did not 
affect cell differentiation during development.  lrp1 MO-injected cells were excluded 
from the tip cell position within venous network located in the caudal vein plexus and 
participated in fewer ventral sprouting events (Figure 6.5C and 6.5D, Figure 6.11H). 
However, there was no obvious defect in the injected cell's ability to contribute to the tip 
cell within the intersegmental vessel, which is predominantly arterial in nature at this 
developmental stage.  Bmp signaling was recently reported to regulate the ventral 
sprouting from the axial vein [12].  This finding, together with our data, suggests that 
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LRP1, similar to Bmp, regulates vein development in a cell-autonomous fashion.  The 
cardiovascular defects observed in LRP1 morphant fish might be due to 
nonautonomous effects of LRP1 and reflect the autonomous requirement of LRP1 in 
venous endothelial function. 
Bmper knockdown in zebrafish leads to diminished levels of Smad1/5/8 
phosphorylation and a dorsalized phenotype consisting of defects in hematopoiesis and 
vascular patterning, reflecting the role that Bmper-mediated Bmp signaling plays during 
embryo gastrulation and vascular development [23,5].  Because the pattern of lrp1a in 
the developing zebrafish embryo mirrors that of bmper, we examined the effect 
of lrp1a knockdown on Bmper-mediated Bmp signaling in lrp1a MO-
injected Tg(kdrl:EGFP)s843 fish using immunohistochemical localization of Smad1/5/8 
phosphorylation.  In wild-type fish, LRP1 expression was localized to the dorsal aorta, 
caudal vein, and caudal artery, whereas the expression of LRP1 protein was 
significantly reduced in lrp1a morphant fish (Figure 6.5E).  In wild-type fish, the signal 
for phosphorylated Smad1/5/8 was mainly localized to the dorsal longitudinal 
anastomotic vessel, dorsal aorta, caudal artery, and some at intersegmental vessel and 
caudal vein (Figure 6.5F).  In contrast, lrp1aknockdown decreased Smad1/5/8 
phosphorylation in these regions (Figure 6.5F), indicating that LRP1, similar to Bmper, 
is required for Bmp-dependent events in vascular development 
 
Discussion 
The data presented in this report is a continuation of our previous work designed 
to elucidate the molecular mechanisms involved in Bmper regulation of Bmp signaling.  
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Here we present data supporting a model in which LRP1 acts as an endocytic receptor 
for Bmper, facilitating the formation and internalization of the Bmp4/BMPR signaling 
complex.  Receptor endocytosis plays a critical role not only in the control of receptor 
protein levels at the cell surface and in the regulation of signaling pathways [24].  
Similar to the case of endocytosis of transforming growth factor-β and epidermal growth 
factor [24], we believe that, in the case of Bmp4 signaling, clathrin-coated pits and early 
endosomes are signaling compartments, whereas late endosomes and lysosomes are 
sites where signaling is eventually blocked.  Furthermore, our data support a model in 
which the magnitude and rate of LRP1-dependent endocytosis and the association of 
LRP1 and Bmp receptors, regulated by the Bmper:Bmp4 stoichiometric ratio, are critical 
factors determining the endocytic route of the Bmp4 signaling complex.  
Previous studies have demonstrated that regulators of Bmp signaling modulate 
Bmp signaling using a spatial gradient effect that covers the distance of many cells [25].  
In contrast, our data suggest that the mechanism for Bmper's regulation of Bmp4 
signaling operates at the single cell level and involves a negative feedback loop within 
the same cell.  For example, when Bmp4 is released it is bound by extracellular Bmper 
that initially is substoichiometric.  Bmp4 together with Bmper binds to BMPRs and is 
subsequently endocytosed and recycled via an LRP1-dependent mechanism, which 
promotes the activation of Bmp4 signaling.  Bmp signaling results in a plethora of 
cellular responses, including upregulation of Bmper expression [26].  As Bmp4 signaling 
continues, more Bmper is released into the extracellular environment until the 
intercellular concentration of Bmper eventually exceeds that of Bmp4.  When this 
happens, the endocytosed Bmper/Bmp4/ALK6 complex is routed to lysosomes where it 
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is degraded, thereby resulting in inhibition of Bmp4 signaling.  In this way, each cell 
involved in the Bmp4 signaling event responds in a tightly controlled manner. 
Although the focus of this report has been the effect of LRP1 on Bmp4 signaling, 
it is entirely possible that Bmper/Bmp4 may also have an effect on LRP1 signaling.  
More than 40 ligands have been identified for LRP1, encompassing multiple cellular 
functions such as the regulation of lipid metabolism, cell migration, blood-brain barrier 
integrity, and neuronal homeostasis [14].  Our observation that both Bmper and ALK6 
bind to the α chain of LRP1, which is responsible for ligand uncoupling [14], raises the 
interesting possibility that Bmper and Bmps may influence the signaling mechanisms 
carried out by LRP1.  This is an intriguing thought, especially given the evidence that 
LRP1 regulates atherosclerosis via modulation of PDGF and transforming growth factor-
receptor functions [14].  A potential interaction or competition between previously 
identified LRP1 signaling pathways and Bmp-mediated pathways remains a topic of 
future research. 
We have demonstrated that LRP1, through its effect on Bmp signaling, is 
essential for cardiovascular development in zebrafish.  The expression pattern of lrp1 in 
developing embryos is remarkable for several reasons.  lrp1 is expressed in regions 
known for their high Bmper/Bmp activity and areas of known vasculogenesis [5].  This 
pattern places lrp1 at a time and location in which it could interact with Bmper and 
therefore mediate Bmper/Bmp signaling.  This observation is confirmed by the similar 
phenotype of lrp1- and bmper deficient fish.  Knockdown of either lrp1 or bmper leads to 
a similar abnormality in vascular development, such as the compromised caudal vein 
plexus and aberrant intersegmental vessels.  However, bmper morphants also exhibit a 
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reducednumber of gata1 expressing hematopoietic precursor cells and circulating blood 
cells [5].  Whereas these cell types were distributed in a disorganized pattern in lrp1 
morphants, the actual cell number remained similar to wild-type embryos.  The subtle 
differences in the expression pattern and knockdown phenotype of LRP1, compared to 
Bmper, could be attributed to the activation of LRP1 by its other ligands.   
Collectively, our data suggest that LRP1 plays a requisite role in Bmper-mediated 
regulation of Bmp4 signaling byacting as an endocytic receptor for Bmper and 
mediating the endocytosis of the Bmper/Bmp4/BMPR complex.  Based on these 
observations, we propose the following working model to explain the role of LRP1 in the 
regulation of Bmper- mediated Bmp4 signaling (Figure 6.6).  In the absence of ligand, 
ALK6 and LRP1 are associated, blocking the assembly of an active BMPRII/ALK6 
complex (Figure 6.6A, left).  However, in the presence of Bmp4 (Figure 6.6A, middle), 
ALK6 dissociates from LRP1 and heterodimerizes with BMRPII.  The receptor complex 
is then endocytosed via clathrin-coated pits in an LRP1-independent manner and 
sequestered within endosomes where Bmp4-dependent Smad1/5/8 activation occurs 
[20].  When the concentration of Bmper is substoichiometric, Bmper/LRP1 forms a 
transient holocomplex with Bmp4/ALK6/BMPRII (Figure 6.6B), promoting the Rab4-
dependent endocytic fast recycling and therefore enhancing downstream signaling 
(Figure 6.6D).  The signaling reaction continues to completion, possibly by termination 
of Smad1/5/8 phosphorylation via phosphatase activation.  We speculate that, at the 
completion of the signaling reaction, the various components of the Bmper/Bmp4 
signaling complex are recycled back to the cell membrane (Figure 6.6D, red route), 
where they would be available for future signaling events.  This pathway would explain 
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the ability of substoichiometric concentrations of Bmper to activate Bmp4 signaling.  
When the concentration of Bmper is suprastoichiometric, the association of LRP1 with 
ALK6 increases, but that of ALK6 with BMPRII decreases (Figure 6.6C).  The LRP1-
dependent endocytosis of a transient Bmper/Bmp4/ALK6/LRP1 holocomplex leads to 
the degradation of the Bmper/Bmp4 signaling complex and early termination of Bmp4 
signaling activity (Figure 6.6E, green route).  We therefore propose that the different 
components of the transient Bmp4/Bmper receptor holocomplex may be the 
determining factor in deciding which endocytic sorting routes are used in the presence 
of sub- versus suprastoichiometric concentrations of Bmper.  Bmper was recently 
reported to preferentially regulate Bmp9/ALK1 signaling in endothelial cells [27].  
Whether LRP1 is required for Bmper-modulated Bmp9/ALK1 signaling and how Bmp9 
regulates Bmp4/Bmper/BMPR/LRP1 complex formation needs future investigation.  
Moreover, the mechanisms behind the receptor dependent endocytic sorting described 
remain unknown.  The different components of the transient holocomplex may recruit 
different scaffolding proteins, thereby influencing the intracellular route of receptor 
complex processing.  Alternatively, intracellular routing of the Bmper/Bmp4 signaling 
complex may be regulated by posttranslational modification of LRP1, which may occur 
differentially depending on which components comprise the Bmper/Bmp4 receptor 
complex.  For example, LRP1 contains an NPxY motif in its cytoplasmic tail that lies 
proximal to the plasma membrane.  This NPxY motif is a sorting nexin 17-binding motif 
that help sort LRP1-contained endosomes during the receptor recycling process.  If this 
motif is mutated, LRP1-containing endosomes cannot be recycled and become targets 
of lysosomal degradation [28].  LRP1 endocytosis can also be regulated by a cAMP-
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dependent protein kinase A-mediated serine phosphorylation on its cytoplasmic tail [29].  
It is possible that the different Bmper/Bmp4 receptor complexes formed in the presence 
of high and low concentrations of Bmper may influence either the phosphorylation of the 
LRP1 cytoplasmic tail or the recruitment of endosome sorting proteins such as sorting 
nexin 17, which in turn may result in differential intracellular sorting routes.  Although 
additional work is needed to fully elucidate the exact mechanism for the different sorting 
processes by which LRP1 regulates Bmper/Bmp4 signaling, LRP1-dependent 
endocytosis is clearly critical for all aspects of Bmper-mediated Bmp4 signaling, and the 
stoichiometric ratio of Bmper to Bmp4 is a key to determine whether Bmp signaling is 
activated or inhibited. 
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Figure 6.2: LDL receptor-related protein 1 (LRP1) is required for bone 
morphogenetic protein endothelial cell precursor-derived regulator (Bmper) 
endocytosis.  
(A) Time course of nondenatured cell lysates from Bmper-treated mouse 
endothelial cells (MECs) (6 nmol/L) were analyzed by Western blotting.  (B) 
Quantification of Bmper protein band intensity in A.  *, compared to nontreated control 
(Ctrl) sh-MECs, P<0.02, n=3; #, compared to LRP1-knockdown MECs treated 
similarly, P<0.05, n=3.  (C) Nondenatured cell lysates from MECs treated with 
increasing doses of Bmper were analyzed by Western blotting.  (D) Quantification of 
Bmper protein band intensity in C. *, compared to nontreated control sh-MECs, P<0.05; 
#, compared to LRP1-knockdown MECs treated similarly,P<0.02, n=3.  (E) Bmper-
treated MECs (15 min) were analyzed by confocal imaging for the colocalization of 
Bmper (green), LRP1 (red), and EEA1 (purple), indicated by the arrows.  Scale bars: 5 
μm.  NTD indicates amino-terminal domain; CTD, carboxyl-terminal domain; DAPI, 4,6-
diamidino-2-phenylindole.  
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Figure 6.4: LDL receptor-related protein 1 (LRP1)-mediated endocytosis is 
required for the bone morphogenetic protein endothelial cell precursor-derived 
regulator (Bmper)-dependent regulation of bone morphogenetic protein (Bmp)4 
downstream signaling.  
(A) Endocytosis is required for both promoting and inhibiting Bmp function of 
Bmper.  Mouse endothelial cells (MECs) were pretreated with chlorpromazine (CPM) or 
chloroquine (CQ) and then treated with Bmp4 (0.6 nmol/L) and Bmper for 15 min 
(chlorpromazine [CPM]) or 120 min (CQ) at 10 nmol/L (Bmper alone); 0.3 nmol/L (BB-
sub [substoichiometric Bmper]); 10 nmol/L (BB-supra [Bmper suprastoichiometric]).  
Cell lysates were analyzed by Western blotting.  (B) Rab4 is required for Smad1/5/8 
phosphorylation induced by Bmp4 and substoichiometric Bmper.  Lysates of MECs 
transfected with control (Ctrl) or Rab4 siRNA and treated with Bmp4 and Bmper (15 
min) were analyzed by Western blotting.  (C) LRP1 is required for Bmper/Bmp 
internalization and Bmper-dependent Bmp downstream signaling.  Lysates of LRP1-
knockdown or control MECs treated with Bmp4 and Bmper (30 min) were analyzed by 
Western blotting.  (D) Lysates of MECs treated with Bmp4 and Bmper for 15 min were 
immunoprecipitated with an anti-Bmp receptor (BMPR)II antibody and analyzed by 
Western blotting.  (E) The association of LRP1 and ALK6 is regulated on the different 
treatment of Bmp4 and Bmper.  Lysates of MECs following Bmp4 and Bmper 
treatments for 15 min were immunoprecipitated with the mouse anti-LRP1β antibody 
and analyzed by Western blotting.  (F) MECs were subjected to the in vitro Matrigel 
angiogenesis assay.  *, compared to the same MECs at control condition, P<0.05. #, 
compared to the same MECs treated with Bmp4, P<0.01. n=3. Scale bar: 100 μm. 
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Figure 6.8. LRP1 is required for Bmper endocytosis.  
(A) Non-denatured cell lysates from cells treated with Bmper for different time 
periods were analyzed for Bmper protein level by Western blotting with an anti-Bmper 
antibody.  (B) Quantification of Bmper protein band intensity in A.  *, compared to non-
treated wild-type MEFs, P<0.02, n=3; #, compared to LRP1 null MEFs treated similarly, 
P<0.05, n=3 independent experiments.  (C) Non-denatured cell lysates from cells 
treated with increasing doses of Bmper were analyzed for Bmper protein level by 
western blotting with an anti-Bmper antibody.  (D) Quantification of Bmper protein band 
intensity in C.  *, compared to non-treated wild-type MEFs, P<0.05; #, compared to 
LRP1 null MEFs treated similarly, P<0.02, n=3 independent experiments.  (E) Bmper-
treated MECs (15 minutes) were analyzed by confocal imaging for the co-localization of 
Bmper (green), LRP1 (red) and EEA1 (purple).  Colocalization of these three proteins is 
indicated by blue 14particles (arrow).  These are the representative images of three 
independent experiments.  (F) MECs treated with Bmper for 90 minutes were analyzed 
by confocal imaging for the co-localization of Bmper (green), LRP1 (red) and Rab7 
(purple).  Colocalization of these three proteins is indicated by blue particles (arrow).  
These are the representative images of three independent experiments.  (G) MEFs 
treated with Bmper for 5 minutes were analyzed by confocal imaging for the co-
localization of Bmper (green), LRP1 (red) and EEA1 (purple).  Colocalization of these 
three proteins results in blue immunofluorescence, as indicated by the arrows.  Scale 
bars: 5 µm.  (H) Subcellular fractionation experiments were performed to confirm the 
location of Bmper and LRP1 in MECs.  Eleven serial membrane fractions prepared from 
5 nmol/L Bmper-treated control (Ctrl sh-MEC) or LRP1 shRNA stably transfected MECs 
(LRP1 sh-MEC) were fractionated on a self-generated Optiprep gradient (10%, 20%, 
30%) and immunoblotted with antibodies against proteins-Bmper and LRP1α, and that 
enriched in plasma membrane (FLK1); early endosomes (EEA1); or late endosomes 
(Rab7).  Optiprep gradient fractionation resulted in Bmper and LRP1α mainly 
cofractionating with Flk1 (plasma membrane marker), EEA1 (early endosome marker) 
and Rab7 (late endosome marker).  In LRP1-knockdown MECs, we observed 
considerably less Bmper localized in plasma membrane and endosomal fractions.  
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#, compared to MECs treated with Bmp4 alone, P<0.05. **, P<0.05. n=3.  (D) 
Quantitative analysis of Figure 4A "CQ" experiment (lower panel).  *, compared to same 
MECs at control condition, P<0.05.  #, compared to MECs treated with Bmp4 alone, 
P<0.05.  **, P<0.05. n=3.  (E) MECs were pretreated with 100 nmol/L bafilomycin 
A1(BafA1) for 6 hours and then subjected to the indicated treatments of Bmp4 and 
Bmper for 2 hours.  The cell lysates were analyzed by Western blotting with antibodies 
for pSmad1/5/8 and Smad1.  *, compared to same MECs at control condition, P<0.05.  
#, compared to MECs treated with Bmp4 alone, P<0.05.  **, P<0.05.  n=3.  (F) 
Quantitative analysis of Figure 4C.  *, compared to same MECs at control condition, 
P<0.05.  #, compared to MECs treated with Bmp4 alone, P<0.05.  **, P<0.05.  n=3.  (G) 
Quantitative analysis of Figure 4D.  *, compared to same MECs at control condition, 
P<0.05.  **, P<0.05.  n=3.  (H) The role of LRP1 in the regulation of ALK6 binding to 
other Bmp type II receptors such as the activin receptor type II (ACVRII) was examined.  
Lysates of MECs treated with Bmp4 (0.6 nmol/L) and Bmper (0.3 nmol/L or 10 nmol/L) 
for 15 minutes were immunoprecipitated with an anti-ACVRII antibody and analyzed by 
Western blotting with anti-ALK6 and ACVRII antibodies.  Interestingly, the pattern of 
ALK6 binding to ACVRII was opposite from that of ALK6 and BMPRII (Figure 4D).  At 
the basal state, ALK6 was associated with ACVRII, however the level of their binding 
significantly decreased in LRP1-knockdown MECs.  Additionally, the binding of ALK6 
and ACVRII was promoted upon Bmp4 and Bmper treatment in LRP1-knockdown 
MECs.  Therefore, we speculate that LRP1 is required for the dynamic balance of Bmp 
receptors on the membrane.  (I) Lysates of MEFs treated with Bmp4 (0.6 nmol/L) and 
Bmper (0.3 nmol/L or 10 nmol/L) for 15 minutes were immunoprecipitated with an 
antiBMPRII antibody and analyzed by Western blotting with anti-ALK6 and BMPRII 
antibodies.  The binding of ALK6 and BMPRII was similar in MEFs, except samples 
treated with Bmper alone demonstrated no change in the association of ALK6 and 
BMPRII in MECs (Figure 4D) but an increased association in MEFs, suggesting that the 
expression levels of Bmp receptors and LRP1 possess subtle difference between MEFs 
and MECs.  (J) Quantitative analysis of Figure 4E.  *, compared to MECs at control 
condition, P<0.05.  n=5.  (K) MECs were subjected to the Boyden chamber migration 
analysis with Bmp4 (0.6 nmol/L) and Bmper as chemoattractants.  *, compared to the 
same type of MECs at control condition, P<0.001.  #, compared to the same type of 
MECs treated with Bmp4, P<0.001.  n=4.  (L) MECs were subjected to the Boyden 
chamber migration analysis with Bmp4 (4 nmol/L) as chemoattractants, and neutralizing 
Bmp4 antibody (10 µg/mL) was used to co-treat cells and block Bmp4 activity.  *, 
compared to MECs at control condition, P<0.05.  #, compared to MECs treated with 
Bmp4, P<0.05.  n=3.  
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Figure 6.11. LRP1 is required for vascular development in zebrafish. 
(A) RNA expression of lrp1a in a whole-mount zebrafish embryo, analyzed by in-
situ hybridization using a lrp1a-specific antisense probe.  The sense probe of lrp1a was 
used as a negative control Scale bar: 100 µm.  (B) PCR analysis of zebrafish embryo 
RNAs demonstrates the knockdown of lrp1a or lrp1b or both with their specific MOs.  
(C) Loss of lrp1a and p53 results in a similar vascular phenotype to the loss of lrp1a, 
suggesting there is no off-targeting effect with lrp1a MO.  lateral views of 
Tg(kdrl:EGFP)s843;Tg(gata1:dsRed)sd2 fish embryo tails at 48 hpf were presented.  The 
arrowhead represents the blood circulation with a changed route; the arrow represents 
the disrupted intersegmental vessel.  Scale bar: 100µm.  (D) PCR analysis of zebrafish 
embryo RNAs demonstrates the knockdown of lrp1a after injection of lrp1a and p53 
MOs.  (E) PCR analysis of zebrafish embryo RNAs demonstrates the knockdown of 
lrp1a(e3i3) with its specific MOs.  (F) The cardiovascular defects observed with lrp1a 
MO targeting the e1i1 splice site were confirmed with an alternative MO -lrp1a(e3i3), 
targeting the e3i3 splice site.  It suggests that lrp1a MO is specific.  Images are lateral 
views of Tg(kdrl:EGFP)s843;Tg(gata1:dsRed)sd2 zebrafish embryo tails at 24 hpf.  Scale 
bar: 100 µm.  (G) Loss of lrp1a, lrp1b or both results in a similarly disrupted vascular 
phenotype.  Images are lateral views of Tg(kdrl:EGFP)s843 
zebrafish embryo tails at 24 hpf.  The arrowheads represent the causal vein plexus with 
branches; the arrows represent filopodia located on the front edge of vessel plexus.  
Scale bar: 100 µm.  (H) The wild-type recipient embryos of Tg(kdrl:EGFP)s843 were 
transplanted with control or lrp1 MO-injected donor cells (labeled with rhodamine-
dextran).  At 32 hpf, images of lateral views were taken with fluorescent microscopy.  
White arrowheads represent the donor cells located at cardinal vein plexus.  Scale bar: 
75 µm.  LDA, lateral dorsal aorta.  CCV, common cardinal vein.  ACV, anterior cardinal 
vein.  Se, intersegment vessel.  DLAV, dorsal longitudianl anastomotic vessel.  DA, 
dorsal aorta.  CV, caudal vein.  CA, caudal artery.  PCV, posterior cardinal vein.  
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CHAPTER 7 
Vascular Endothelial Growth Factor Signaling Regulates the Segregation of 
Artery and Vein via ERK Activity During Vascular Development 
 
 
Summary 
Vasculogenesis is the formation of a vascular cord, which is followed by 
arterio-venous segregation and lumenization of axial vessels. Little is known about 
the cues that promote this early separation of progenitors into differentiated, 
functional vessels. Here we further define the role of Vegf-A signaling in this 
process. Furthermore, we show interrogate the role of downstream effectors of Kdrl, 
Extracellular-signal-signal-related kinase (Erk) and phosphatidylinositol-3 kinase 
(PI3K), in this process using chemical genetic methods. 
 
Introduction 
The vascular network, which provides the essential functions of delivering 
oxygen and removing metabolic waste products, is one of the first organs to emerge 
in embryos. In vertebrates, the vascular system is formed by two distinct processes, 
vasculogenesis, de novo formation of blood vessels, and angiogenesis, the 
formation of new blood vessels from preexisting vessels. During development, 
endothelial cells, the innermost lining of the vascular network, form transient 
aggregates known as the vascular cord in the midline [1,2]. Endothelial cells within 
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the vascular cord start to express arterial and venous specific markers as early as 
E11.5 in mouse [3], and as early as 18 hours post-fertilization (hpf) in zebrafish [1,4], 
preceding the emergence of morphologically distinct arteries and veins [5]. 
Subsequently, developing vasculature acquires the stereotypic hierarchy; arteries 
and veins are physically separated and only connected by the capillaries.  Failure to 
segregate arteries and veins results in ectopic shunts connecting these two types of 
vessels, a pathological condition known as arteriovenous malformation (AVM) [6].  
While the etiology of AVM remains largely unknown, recent advances start to 
unravel the molecular and cellular mechanisms that underlie the sorting of arterial 
and venous endothelial cells.  Attenuation of several genes has shown to cause 
failure in segregation of axial vessels in vertebrates.  For instance, mutation in Dll4 
in mice causes improper segregation of the dorsal aorta and the cardinal vein, 
creating arteriovenous shunts [7,8].  Similarly, simultaneous reduction of sox7 and 
sox18 genes resulted in improper segregation of the dorsal aorta and the cardinal 
vein[9,10,11].  In all cases, both differentiation of arterial/venous endothelial cells 
and the segregation of the axial vessels were affected, suggesting that these two 
events are tightly linked developmental processes.  
Recent studies have shown that arterial and venous endothelial cells respond 
differently to various signaling molecules, which might be the main driving force for 
the segregation of arteries and veins during development.  For instance, Vascular 
Endothelial Growth Factor-A (Vegf-A) and Vascular Endothelial Growth Factor-C 
(Vegf-C) signaling preferentially activates dorsal migration of arterial endothelial cells 
and ventral migration of venous endothelial cells respectively, within the vascular 
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cord, therefore, synergistically promoting the segregation of axial vessels in 
zebrafish embryos [2].  In addition, the repulsive interaction between EphrinB2 and 
EphB4 has been shown to be critical in regulating the segregation of arterial 
endothelial cells from the venous endothelial cells in developing mouse embryo.  
The dorsal aorta in mice lacking EphrinB2 or EphB4 contained venous endothelial 
cells, leading to the enlarged dorsal aorta at the expense of the cardinal vein [12].  
Later in development, we have recently demonstrated that arterial and venous 
endothelial cells exhibit different responses to Vegf-A and Bone Morphogenetic 
Protein (Bmp) signaling [13].  While Bmp signaling induces angiogenesis within 
venous endothelial cells, arterial endothelial cells remain unaffected.  Conversely, 
Vegf-A signaling preferentially facilitates angiogenesis within arterial endothelial cells 
without activating venous endothelial cells.  Collectively, these reports indicate 
distinct molecular nature of arterial and venous endothelial cells.  However, it is 
unclear how differences in molecular characteristics of arterial and venous 
endothelial cells contribute to the segregation of axial vessels.  Moreover, it is 
unknown which signaling pathways regulate the segregation of axial vessels during 
development.  Considering its importance during vascular development, it is likely 
that VEGF-A signaling may provide a pivotal function in this process.  
In this study, we used zebrafish as a model system to investigate the role of 
Vegf-A signaling during the segregation of axial vessels.  We find that reduction in 
Vegf-A signaling activity led to a failure in the segregation of arteries and veins.  
Moreover, we find that inhibition of Erk, which are known to function downstream of 
Vegf-A signaling pathway [4] yield similar defects in developing zebrafish, while 
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activation of Erk in embryos with a reduced level of Vegf-A activity can restore the 
segregation defects, indicating that activation of Erk by Vegf- A signaling is essential 
for the proper segregation of axial vessels.  Taken together, our data demonstrate 
the critical role of Vegf-A signaling during the segregation of axial vessels.  
 
Experimental Methods 
Zebrafish Husbandry 
Zebrafish (Danio rerio) embryos and adults were raised and maintained as 
previously described under IACUC guidelines[14].  
Microinjection and chemical treatment 
Morpholinos (MO) (Gene Tools, LLC) were injected into 1-cell-stage 
Tg(kdrl:EGFP) embryos as previously described [1].  The sequences of MOs used in 
this study are; kdrl: 5'- CACAAAAAGCGCACACTTACCATGT-3',  
vegf-aa: 5'-CTCGTCTTATTTCCGTGACTGTTTT-3'[15],  
kdr: 5'- GTTTTCTTGATCTCACCTGAACCCT-3',  
ephrinb2a: 5'- CGGTCAAATTCCGTTTCGCGGGA-3'[16],  
plcγ: 5'-ATTAGCATAGGGAACTTACTTTCG-3' [17].  
For chemical treatment, embryos were treated from the 10 somite stage to 30 hours 
post fertilization (hpf) unless noted otherwise, and fixed overnight in 4% 
paraformaldehyde (PFA).  To transiently express constitutively active MEK (CA-
MEK) [18] in endothelial cells, CA-MEK was subcloned into the Gateway middle 
entry vector and recombined into kdrl promoter containing vector.  The resulting 
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construct allows kdrl promoter regulated, transient expression of CA-MEK in a 
subset of endothelial cells in injected embryos.  
IP3 uncaging and analysis 
Caged IP3 (800μM) was co-injected with caged-fluorescein (0.2% w/v) 
dextran to assess uncaging and Vegf-a morpholino.  Uncaging was done using the 
UV channel of a Leica Confocal Microscope (Michael Hooker Miscroscopy Institute) 
at the 18-somite stage.  Rescue of morphant phenotype was assessed at the 30 hpf 
stage.  
Immunohistochemistry, western blot, and in situ hybridization 
Immunohistochemistry and in situ hybridization were performed as previously 
described [1].  Anti-β-catenin antibody (1:150, BD Biosciences) was used to show 
cell boundaries.  
Phenotypic analyses 
30 hpf zebrafish embryos were analyzed by fluorescent stereomicroscope to 
examine the vascular morphology.  For those appear to contain a single axial 
vessels, transverse sections from 10th somite to 18th somite of 30 hpf zebrafish 
embryos were analyzed by confocal microscopy.  Minimum of ten sections per 
embryos were analyzed.  If the embryo had more than seven sections with single 
axial vessels, it was counted as ‘embryos with a single axial vessel’.  
Quantitative RT-PCR 
Quantitative RT-PCR was performed as previously reported [19].  The trunk 
region (above the yolk extension) of the embryos was dissected and RNA was 
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extracted, and pre-tested qRT-PCR primers (Applied biosystems) were used to 
detect the gene expression  
 
Results and Discussion 
To examine the function of Vegf-A signaling during segregation of axial 
vessels, we attenuated the function of well characterized components of Vegf-A 
signaling in Tg(kdrl:EGFP)s843 embryos[1].  Blocking Vegf-A signaling by injecting 
morpholino (MO) against vegf-aa or plcγ caused failure in segregation of axial 
vessels (Figure 7.1A to C), indicating that Vegf-A signaling plays an important role in 
the segregation of axial vessels.  
In zebrafish genome, two functional orthologs of Vascular Endothelial Growth 
Factor Receptor 2 (VEGFR2/KDR), vegfr2/kdr and vegfr4/kdrl are present [20].  
Previously, it has been shown that the function of Kdr appears to be largely 
dispensable for the specification of arterial endothelial cells, although Kdrl and Kdr 
might function redundantly to promote segmental artery formation [21].  Therefore, it 
is plausible that Kdrl and Kdr may have a distinct role in transducing the activity of 
Vegf-A signaling during axial vessel segregation in zebrafish.  To examine this 
possibility, we selectively inhibited Kdrl or Kdr during development, and analyze the 
resulting vascular phenotype (Figure 7.2). 
While embryos injected with kdrl MO contained only a single axial vessel, 
those injected with kdr MO injected embryos had a distinct dorsal aorta and axial 
vein, suggesting that the function of Kdr may be dispensable for the segregation of 
axial vessels (Figure 7.2B and 7.2C).  Furthermore, the severity and penetrance of 
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defects on axial vessel segregation in embryos co-injected with kdrl and kdr MO 
were comparable to those of embryos injected with kdrl MO alone, suggesting that 
the contribution of Kdr to the segregation of axial vessels is likely to be minor.  
Interestingly, blocking either Kdrl or Kdr function led a significant reduction in 
the expression level of arterial and venous specific genes, indicating that both 
Vegfr2/KDR orthologs are required to promote or maintain the expression of 
differentiated endothelial cell markers (Figure 7.2D).  Taken together, it seems that 
both Kdr and Kdrl are required to maintain and/or initiate differentiation of endothelial 
cells, while Kdrl appears to be the main Vegf-A receptor during segregation of axial 
vessels.  
One of the main downstream effector of Vegf-A signaling is Protein Kinase C 
(PKC), which is activated by diacylglycerol (DAG) [22].  It has been shown that 
inhibition of PKC by chemical antagonists blocks the pro-angiogenic effects of Vegf-
A signaling.  To test whether PKC is also involved in transducing Vegf-A signaling 
during segregation of axial vessels, we attenuated the level of PKC activity.  14 hpf 
wild-type zebrafish embryos were treated with 60μM Bisindolylmaleimide, a known 
antagonist of PKC, for 16 hours [23].  As a positive control, SU5416, a well 
characterized chemical antagonist of VEGFR2, was used.  In embryos treated with 
SU5416, the axial vessels failed to segregate as expected (n=20) (Figure 7.3A and 
7.E).  Similarly, we find that failure in segregation of axial vessels failed in embryos 
with reduced PKC activity (n=75) (Figure 7.3B and 7.3E), indicating that PKC is an 
essential mediator for Vegf-A signaling during segregation of axial vessels.  
141 
 
Two prominent downstream effectors of PKC activity in the Vegf-A signaling 
cascade is Map2k1/Erk and Akt/PI3K, which elicit a variety of cellular responses 
including increased vascular permeability, elevated eNOS production, and initiation 
of Vegf-A target genes [24].  To determine the function of these two signaling 
pathways in transducing Vegf-A signaling during the segregation of axial vessels, we 
also attenuated the activity of Map2k1/Erk or Akt/PI3K, and examined the resulting 
vascular phenotype.  
When embryos were treated with 25μM U0126, a chemical antagonist of 
Map2k1/Erk [25], from 14 to 30 hpf, a significant portion of the embryos had a single 
axial vessel with impaired circulation, which was reminiscent of the phenotype of 
embryos with compromised Vegf-A signaling (n=105), suggesting that the 
Map2k1/Erk activity is required to mediate Vegf-A signaling during the segregation of 
axial vessels (Figure 3C and E).  
Similarly, to investigate the contribution of Akt/PI3K in antagonizes 
Map2k1/Erk in a similar manner to modulate Vegf-A signaling during the segregation 
of axial vessels, we treated embryos from 14 to 30 hpf with 30μM LY294002, a 
chemical antagonist that inhibits phosphorylation of Akt therefore attenuating PI3K 
activity (n=98) [26].  Inhibition of PI3K activity at this stage caused vascular defects 
comparable to Map2k1/Erk inhibition (Figure 7.3D and 7.3E).  Approximately 70 
percent of the embryos treated with LY294002 displayed a single axial vessel 
(Figure 7.33E).  Taken together, our data indicate that effects of Vegf-A signaling 
during the segregation of the axial vessels require the activity of PKC, Erk, and 
PI3K.  
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To determine if the effect seen when PI3K was inhibited was mediated by 
IP3, we used UV-photoactivation caged IP3 in small two somite segments at 18.5 
hpf.  Activation of IP3 in the developing vascular cord did not rescue the effect of the 
kdrl morpholinos.  That is, rescue of arteriovenous segregation was never observed 
within the uncaged region (N=54) similar to mock control with only caged fluorescein 
dextran (N=34).  
To examine whether activation of these downstream effectors is sufficient to 
initiate segregation of axial vessels in embryos with a reduced level of Vegf-A 
signaling, we utilized chemical genetics approach.  To test whether the activation of 
PKC is sufficient to bypass the requirement of Vegf-A signaling, kdrl MO injected 
embryos were incubated with 16μM 12- O-tetradecanoylphorbol-13-acetate (TPA) 
[27], a chemical agonist of PKC from 14 to 30 hpf.  As a positive control, we used 
GS4012, a chemical agonist of Vegf-A signaling.  While kdrl MO injected embryos 
incubated with DMSO (empty vehicle) contained a single axial vessel (n=40, Figure 
7.4A and 7.4B), 77 percent of kdrl MO injected embryos treated with GS4012, and 
86 percent of kdrl MO injected embryos incubated with TPA had a clearly separate 
dorsal aorta and axial vein (n=55 for GS4012, and n=42 for TPA, Figure 7.4A and 
7.4B).  Therefore, activation of PKC is sufficient to alleviate defects on the 
segregation of axial vessels caused by reduced Vegf-A signaling.  
To further examine the function of Map2k1/Erk in the segregation of axial 
vessels, constitutively active MEK (CA-MEK) was selectively expressed in 
endothelial cells in kdrl MO injected embryos (Figure 7.4C and 7.4D) [18].  Since 
MEK induces activation of Map2k1/Erk, ectopic expression of CA-MEK in endothelial 
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cells should alleviate the phenotype of kdrl MO injected embryos.  While less than 
two percent of embryos co-injected with a vector encoding Blue Fluorescent Protein 
(BFP) and kdrl MO contained two axial vessels at 28 hpf (Figure 7.4E), a significant 
portion (38%) of embryos co-injected with the CA-MEK construct and kdrl MO had 
clearly distinguishable axial vessels (Figure 7.4E), suggesting that Map2k1/Erk 
activity is critical for the segregation of the axial vessels, but dispensable for the 
maintenance of the arterial or venous specific gene expression downstream of Vegfr 
signaling.  
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